TW201041882A - Salt of ABT-263 and solid-state forms thereof - Google Patents
Salt of ABT-263 and solid-state forms thereof Download PDFInfo
- Publication number
- TW201041882A TW201041882A TW099113921A TW99113921A TW201041882A TW 201041882 A TW201041882 A TW 201041882A TW 099113921 A TW099113921 A TW 099113921A TW 99113921 A TW99113921 A TW 99113921A TW 201041882 A TW201041882 A TW 201041882A
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- abt
- bis
- doc
- composition
- Prior art date
Links
- 229950004847 navitoclax Drugs 0.000 title claims abstract description 87
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 title claims abstract description 87
- 150000003839 salts Chemical class 0.000 title description 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 52
- 201000011510 cancer Diseases 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims abstract description 6
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims abstract description 6
- 230000002018 overexpression Effects 0.000 claims abstract description 5
- -1 β-green Chemical class 0.000 claims description 99
- 239000000203 mixture Substances 0.000 claims description 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 239000012453 solvate Substances 0.000 claims description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 44
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 25
- 239000013078 crystal Substances 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 19
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 18
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 235000021419 vinegar Nutrition 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 239000000052 vinegar Substances 0.000 claims description 13
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 11
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 11
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 11
- 239000012458 free base Substances 0.000 claims description 10
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 9
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 7
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 201000007455 central nervous system cancer Diseases 0.000 claims description 6
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 6
- 201000003444 follicular lymphoma Diseases 0.000 claims description 5
- 230000036210 malignancy Effects 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000000277 Splenic Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 230000001613 neoplastic effect Effects 0.000 claims description 4
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 230000003381 solubilizing effect Effects 0.000 claims description 4
- 201000002471 spleen cancer Diseases 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 3
- 206010046392 Ureteric cancer Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 201000005969 Uveal melanoma Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 210000000013 bile duct Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 230000002183 duodenal effect Effects 0.000 claims description 3
- 210000000750 endocrine system Anatomy 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 238000007917 intracranial administration Methods 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 210000005229 liver cell Anatomy 0.000 claims description 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000025440 neoplasm of neck Diseases 0.000 claims description 3
- 201000002575 ocular melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000003913 parathyroid carcinoma Diseases 0.000 claims description 2
- 208000017954 parathyroid gland carcinoma Diseases 0.000 claims description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims 2
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000005179 adrenal carcinoma Diseases 0.000 claims 1
- SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 claims 1
- 201000007983 brain glioma Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 238000004807 desolvation Methods 0.000 claims 1
- 238000010586 diagram Methods 0.000 claims 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 208000037959 spinal tumor Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract description 13
- 230000002424 anti-apoptotic effect Effects 0.000 abstract description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 34
- 150000003904 phospholipids Chemical class 0.000 description 28
- 239000003814 drug Substances 0.000 description 26
- 239000002253 acid Substances 0.000 description 24
- 239000003963 antioxidant agent Substances 0.000 description 23
- 235000006708 antioxidants Nutrition 0.000 description 23
- 229940079593 drug Drugs 0.000 description 23
- 239000000047 product Substances 0.000 description 21
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- 230000003078 antioxidant effect Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 229960004641 rituximab Drugs 0.000 description 14
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 14
- 229960004528 vincristine Drugs 0.000 description 14
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 13
- 125000005456 glyceride group Chemical group 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 11
- 239000001913 cellulose Substances 0.000 description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 11
- 235000018417 cysteine Nutrition 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 102000014914 Carrier Proteins Human genes 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 108091008324 binding proteins Proteins 0.000 description 10
- 150000002009 diols Chemical class 0.000 description 10
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 9
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000006184 cosolvent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 9
- 229960004618 prednisone Drugs 0.000 description 9
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 9
- 229940055619 selenocysteine Drugs 0.000 description 9
- 235000016491 selenocysteine Nutrition 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 235000010980 cellulose Nutrition 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 229960004679 doxorubicin Drugs 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 150000002978 peroxides Chemical class 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 229960001231 choline Drugs 0.000 description 7
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229960005420 etoposide Drugs 0.000 description 7
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- IDIDJDIHTAOVLG-UHFFFAOYSA-N S-methyl-L-cysteine Natural products CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000007417 hierarchical cluster analysis Methods 0.000 description 6
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- HVWGGPRWKSHASF-UHFFFAOYSA-N Sulfuric acid, monooctadecyl ester Chemical compound CCCCCCCCCCCCCCCCCCOS(O)(=O)=O HVWGGPRWKSHASF-UHFFFAOYSA-N 0.000 description 5
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 5
- 229960001467 bortezomib Drugs 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 229940099500 cystamine Drugs 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 5
- 229940011051 isopropyl acetate Drugs 0.000 description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- 238000001144 powder X-ray diffraction data Methods 0.000 description 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 5
- 229960002930 sirolimus Drugs 0.000 description 5
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000003490 Thiodipropionic acid Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229960000390 fludarabine Drugs 0.000 description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 229950008882 polysorbate Drugs 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 235000019303 thiodipropionic acid Nutrition 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- NIPWFPYJCVZBSC-UHFFFAOYSA-M 2-hydroxyethyl(trimethyl)phosphanium;chloride Chemical compound [Cl-].C[P+](C)(C)CCO NIPWFPYJCVZBSC-UHFFFAOYSA-M 0.000 description 3
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000009058 Death Domain Receptors Human genes 0.000 description 3
- 108010049207 Death Domain Receptors Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 3
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229910000420 cerium oxide Inorganic materials 0.000 description 3
- 229910052798 chalcogen Inorganic materials 0.000 description 3
- 150000001787 chalcogens Chemical class 0.000 description 3
- 238000002447 crystallographic data Methods 0.000 description 3
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 3
- 229960003901 dacarbazine Drugs 0.000 description 3
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 229960001904 epirubicin Drugs 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229940050411 fumarate Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000002313 intestinal cancer Diseases 0.000 description 3
- 229940099584 lactobionate Drugs 0.000 description 3
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 3
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229960000435 oblimersen Drugs 0.000 description 3
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 3
- 229960002340 pentostatin Drugs 0.000 description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229940075930 picrate Drugs 0.000 description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920003124 powdered cellulose Polymers 0.000 description 3
- 235000019814 powdered cellulose Nutrition 0.000 description 3
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229910021653 sulphate ion Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- HEQRYQONNHFDHG-TZSSRYMLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 HEQRYQONNHFDHG-TZSSRYMLSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical class NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- ZZUBHVMHNVYXRR-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2h-chromen-7-ol Chemical compound C1=CC(O)=CC=C1C1=CC2=CC=C(O)C=C2OC1 ZZUBHVMHNVYXRR-UHFFFAOYSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000051485 Bcl-2 family Human genes 0.000 description 2
- 108700038897 Bcl-2 family Proteins 0.000 description 2
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 229920001491 Lentinan Polymers 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 206010061336 Pelvic neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- FYQZGCBXYVWXSP-LCHZDSEPSA-N [(4S,6R,9E,11R,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4S)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]trideca-1(13),9-dien-2,7-diyn-12-yl] 7-methoxy-2,5-dimethylnaphthalene-1-carboxylate Chemical compound CN[C@H]1[C@@H](O[C@H]2[C@H](OC(=O)c3c(C)ccc4c(C)cc(OC)cc34)C=C3C#C[C@@]4(O[C@@H]4C#C\C=C2/3)[C@@H]2COC(=O)O2)O[C@H](C)[C@H](O)[C@@H]1O FYQZGCBXYVWXSP-LCHZDSEPSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 229960004176 aclarubicin Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229950009084 adecatumumab Drugs 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- KBGIVZVDRZTOOE-UHFFFAOYSA-N aminomethanedithiol Chemical compound NC(S)S KBGIVZVDRZTOOE-UHFFFAOYSA-N 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003080 antimitotic agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229950010993 atrasentan Drugs 0.000 description 2
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 2
- 239000003719 aurora kinase inhibitor Substances 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 108700000711 bcl-X Proteins 0.000 description 2
- 102000055104 bcl-X Human genes 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 229960003008 blinatumomab Drugs 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 2
- 229960003065 bosentan Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 150000004770 chalcogenides Chemical class 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960000605 dexrazoxane Drugs 0.000 description 2
- LFQCJSBXBZRMTN-OAQYLSRUSA-N diflomotecan Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC(F)=C(F)C=C3N=C21 LFQCJSBXBZRMTN-OAQYLSRUSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960001776 edrecolomab Drugs 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical group CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 239000000677 immunologic agent Substances 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 229940124541 immunological agent Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- DXOJIXGRFSHVKA-BZVZGCBYSA-N larotaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 DXOJIXGRFSHVKA-BZVZGCBYSA-N 0.000 description 2
- 229940115286 lentinan Drugs 0.000 description 2
- 125000005645 linoleyl group Chemical group 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960000994 lumiracoxib Drugs 0.000 description 2
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
- 229960003248 mifepristone Drugs 0.000 description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 229920000847 nonoxynol Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 229960002566 papillomavirus vaccine Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960005079 pemetrexed Drugs 0.000 description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229960001221 pirarubicin Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000002770 polo like kinase inhibitor Substances 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 229960004432 raltitrexed Drugs 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 2
- 229950009213 rubitecan Drugs 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- UVZICZIVKIMRNE-UHFFFAOYSA-N thiodiacetic acid Chemical compound OC(=O)CSCC(O)=O UVZICZIVKIMRNE-UHFFFAOYSA-N 0.000 description 2
- 229940035024 thioglycerol Drugs 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960001670 trilostane Drugs 0.000 description 2
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 2
- 229950009811 ubenimex Drugs 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229950009268 zinostatin Drugs 0.000 description 2
- STTNJYHKLLIMKB-UHFFFAOYSA-N $l^{1}-selanylethane Chemical compound CC[Se] STTNJYHKLLIMKB-UHFFFAOYSA-N 0.000 description 1
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- KLZOTDOJMRMLDX-YBBVPDDNSA-N (1r,3s,5z)-5-[(2e)-2-[(1s,3as,7as)-1-[(1r)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C)OCCCC(O)(CC)CC)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C KLZOTDOJMRMLDX-YBBVPDDNSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- MIIFVZVBVFBSNQ-SFHVURJKSA-N (2S)-4-methylsulfanyl-2-(tetradecylamino)butanoic acid Chemical compound C(CCCCCCCCCCCCC)N[C@@H](CCSC)C(=O)O MIIFVZVBVFBSNQ-SFHVURJKSA-N 0.000 description 1
- WQSNCKZPJSHACB-BYPYZUCNSA-N (2r)-2-(methylamino)-3-methylsulfanylpropanoic acid Chemical compound CN[C@H](C(O)=O)CSC WQSNCKZPJSHACB-BYPYZUCNSA-N 0.000 description 1
- RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 description 1
- QWBQSXZHXCWOEY-BQINUBSFSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol;(2r,3r,4r)-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QWBQSXZHXCWOEY-BQINUBSFSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- RIWLPSIAFBLILR-WVNGMBSFSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2r,3s)-2-[[(2s)-2-[[2-[[2-[acetyl(methyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethy Chemical compound CC(=O)N(C)CC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC RIWLPSIAFBLILR-WVNGMBSFSA-N 0.000 description 1
- IGILAMPWVLKGQC-ZETCQYMHSA-N (2s)-2-(butylamino)-4-sulfanylbutanoic acid Chemical compound CCCCN[C@H](C(O)=O)CCS IGILAMPWVLKGQC-ZETCQYMHSA-N 0.000 description 1
- QXOPTIPQEVJERB-JQWIXIFHSA-N (2s)-2-[[5-[2-[(6s)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid Chemical compound C1=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)SC(CC[C@H]2CC=3C(=O)N=C(N)NC=3NC2)=C1C QXOPTIPQEVJERB-JQWIXIFHSA-N 0.000 description 1
- MHFUWOIXNMZFIW-WNQIDUERSA-N (2s)-2-hydroxypropanoic acid;n-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound C[C@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 MHFUWOIXNMZFIW-WNQIDUERSA-N 0.000 description 1
- XUBATEVJJZIKPI-ZETCQYMHSA-N (2s)-4-methylsulfanyl-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCSC XUBATEVJJZIKPI-ZETCQYMHSA-N 0.000 description 1
- ZFKBWSREWJOSSJ-VIFPVBQESA-N (2s)-6,8-dichloro-2-(trifluoromethyl)-2h-chromene-3-carboxylic acid Chemical compound ClC1=CC(Cl)=C2O[C@H](C(F)(F)F)C(C(=O)O)=CC2=C1 ZFKBWSREWJOSSJ-VIFPVBQESA-N 0.000 description 1
- GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 description 1
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- PSXYODYDDXADMZ-UHFFFAOYSA-N (6-oxo-1,7-dihydropurin-2-yl)carbamic acid Chemical compound C(=O)(O)NC=1NC(C=2NC=NC=2N=1)=O PSXYODYDDXADMZ-UHFFFAOYSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- OWOHLURDBZHNGG-YFKPBYRVSA-N (8ar)-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical group O=C1CNC(=O)[C@@H]2CCCN12 OWOHLURDBZHNGG-YFKPBYRVSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- SWQQELWGJDXCFT-PNHWDRBUSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide Chemical compound C#CC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SWQQELWGJDXCFT-PNHWDRBUSA-N 0.000 description 1
- PVCULFYROUOVGJ-UHFFFAOYSA-N 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea Chemical compound CNC(=O)N(S(C)(=O)=O)N(S(C)(=O)=O)CCCl PVCULFYROUOVGJ-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- OUUCZGCOAXRCHN-UHFFFAOYSA-N 1-hexadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC OUUCZGCOAXRCHN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CZDWSKBKCZWXFI-UHFFFAOYSA-N 1-morpholin-4-yl-3-[4-oxo-3-[4-[2-oxo-2-(4-propan-2-ylpiperazin-1-yl)ethoxy]phenyl]-1h-indeno[1,2-c]pyrazol-5-yl]urea Chemical compound C1CN(C(C)C)CCN1C(=O)COC1=CC=C(C=2C=3C(=O)C4=C(NC(=O)NN5CCOCC5)C=CC=C4C=3NN=2)C=C1 CZDWSKBKCZWXFI-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- GOLOHAZKJYGKKQ-UHFFFAOYSA-N 1-nitrodecane Chemical compound CCCCCCCCCC[N+]([O-])=O GOLOHAZKJYGKKQ-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KUFRQPKVAWMTJO-QSTRRNJOSA-N 17-dmag Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-QSTRRNJOSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
- ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical group C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 1
- XNTLXAUHLBBEKP-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound O=C1C(OCCC(C)(O)C)=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=NN1C1=CC=C(F)C(F)=C1 XNTLXAUHLBBEKP-UHFFFAOYSA-N 0.000 description 1
- NHLVRNYCEMTERE-UHFFFAOYSA-N 2-(7H-purin-2-yl)guanidine Chemical compound NC(=N)NC1=NC=C2NC=NC2=N1 NHLVRNYCEMTERE-UHFFFAOYSA-N 0.000 description 1
- PADGNZFOVSZIKZ-UHFFFAOYSA-N 2-(chloromethyl)oxirane;hydrogen carbonate;prop-2-enylazanium Chemical compound NCC=C.OC(O)=O.ClCC1CO1 PADGNZFOVSZIKZ-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N 2-amino-4-methylselanyl-butanoic acid Chemical compound C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical class CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- SOFPIAMTOZWXKT-UHFFFAOYSA-N 2h-1,2,4-triazine-3-thione Chemical compound SC1=NC=CN=N1 SOFPIAMTOZWXKT-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 description 1
- HXHAJRMTJXHJJZ-UHFFFAOYSA-N 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Br)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 HXHAJRMTJXHJJZ-UHFFFAOYSA-N 0.000 description 1
- WJRRGYBTGDJBFX-UHFFFAOYSA-N 4-(2-methyl-3-propan-2-yl-4-imidazolyl)-N-(4-methylsulfonylphenyl)-2-pyrimidinamine Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=N1 WJRRGYBTGDJBFX-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 1
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
- HUNAOTXNHVALTN-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)pyrazole-3-carboxamide Chemical compound CCNC(=O)C1=NNC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C1=CC=C(OC)C=C1 HUNAOTXNHVALTN-UHFFFAOYSA-N 0.000 description 1
- SUDBRAWXUGTELR-HPFNVAMJSA-N 5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-1h-pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OCC1=CNC(=O)NC1=O SUDBRAWXUGTELR-HPFNVAMJSA-N 0.000 description 1
- UPALIKSFLSVKIS-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- GBJVVSCPOBPEIT-UHFFFAOYSA-N AZT-1152 Chemical compound N=1C=NC2=CC(OCCCN(CC)CCOP(O)(O)=O)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 GBJVVSCPOBPEIT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- ZGCSNRKSJLVANE-UHFFFAOYSA-N Aglycone-Rebeccamycin Natural products N1C2=C3NC4=C(Cl)C=CC=C4C3=C(C(=O)NC3=O)C3=C2C2=C1C(Cl)=CC=C2 ZGCSNRKSJLVANE-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 240000000530 Alcea rosea Species 0.000 description 1
- 235000017334 Alcea rosea Nutrition 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 235000017303 Althaea rosea Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 108090000644 Angiozyme Proteins 0.000 description 1
- MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- TXVQMYGCYJCFCS-VWMHFEHESA-N C(CC(O)(C(=O)O)CC(=O)O)(=O)OB.N1[C@@H](CCC1)C(=O)O Chemical compound C(CC(O)(C(=O)O)CC(=O)O)(=O)OB.N1[C@@H](CCC1)C(=O)O TXVQMYGCYJCFCS-VWMHFEHESA-N 0.000 description 1
- LTMLHXVHXJPFRE-INIZCTEOSA-N C(CCCCCCCCCCCC)N[C@@H](CSC)C(=O)O Chemical compound C(CCCCCCCCCCCC)N[C@@H](CSC)C(=O)O LTMLHXVHXJPFRE-INIZCTEOSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- LNHOHOAMYQHOTA-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCOS(=O)(=O)CS(=O)(=O)O Chemical compound CCCCCCCCCCCCCCCCCCOS(=O)(=O)CS(=O)(=O)O LNHOHOAMYQHOTA-UHFFFAOYSA-N 0.000 description 1
- UWPJPUNDKXTEOE-UHFFFAOYSA-N CCCCCCCCCCCCCOS(=O)(=O)CS(=O)(=O)O Chemical compound CCCCCCCCCCCCCOS(=O)(=O)CS(=O)(=O)O UWPJPUNDKXTEOE-UHFFFAOYSA-N 0.000 description 1
- BXDYWXODYFOQPG-UHFFFAOYSA-N CCCCCCCCOS(=O)(=O)CS(=O)(=O)O Chemical compound CCCCCCCCOS(=O)(=O)CS(=O)(=O)O BXDYWXODYFOQPG-UHFFFAOYSA-N 0.000 description 1
- SCAOACGRSIOEFC-UHFFFAOYSA-N CCCCOS(=O)(=O)CS(=O)(=O)O Chemical compound CCCCOS(=O)(=O)CS(=O)(=O)O SCAOACGRSIOEFC-UHFFFAOYSA-N 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- AYYYEWLZYOERAD-UHFFFAOYSA-N CN(C)C1=NC=CC=C1.NN Chemical compound CN(C)C1=NC=CC=C1.NN AYYYEWLZYOERAD-UHFFFAOYSA-N 0.000 description 1
- LBFZBYJFBWDHGW-UHFFFAOYSA-N CNCCNC.NN Chemical compound CNCCNC.NN LBFZBYJFBWDHGW-UHFFFAOYSA-N 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 239000005461 Canertinib Substances 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- OMPIYDSYGYKWSG-UHFFFAOYSA-N Citronensaeure-alpha-aethylester Natural products CCOC(=O)CC(O)(C(O)=O)CC(O)=O OMPIYDSYGYKWSG-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- QXKAIJAYHKCRRA-JJYYJPOSSA-N D-arabinonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(O)=O QXKAIJAYHKCRRA-JJYYJPOSSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 1
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 1
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101000877447 Enterobacteria phage T4 Endonuclease V Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- RVAQIUULWULRNW-UHFFFAOYSA-N Ganetespib Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O RVAQIUULWULRNW-UHFFFAOYSA-N 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 108010023610 IL13-PE38 Proteins 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- IAOZJIPTCAWIRG-UHFFFAOYSA-N Methyl alpha-aspartylphenylalaninate Chemical compound OC(=O)CC(N)C(=O)NC(C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-UHFFFAOYSA-N 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 108010072915 NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 108010025700 PR-171 Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229940122166 Polo-like kinase inhibitor Drugs 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101100528525 Prochlorococcus marinus (strain SARG / CCMP1375 / SS120) rnc gene Proteins 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- QEHOIJJIZXRMAN-UHFFFAOYSA-N Rebeccamycin Natural products OC1C(O)C(OC)C(CO)OC1N1C2=C3NC4=C(Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 QEHOIJJIZXRMAN-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- SLEICVABZPHCJP-UHFFFAOYSA-K S([O-])(O)=O.[Bi+3].S([O-])(O)=O.S([O-])(O)=O Chemical compound S([O-])(O)=O.[Bi+3].S([O-])(O)=O.S([O-])(O)=O SLEICVABZPHCJP-UHFFFAOYSA-K 0.000 description 1
- SBWFWBJCYMBZEY-UHFFFAOYSA-N S-Propyl thioacetate Chemical compound CCCSC(C)=O SBWFWBJCYMBZEY-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BFZKMNSQCNVFGM-UCEYFQQTSA-N Sagopilone Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@H]1C1=CC=C(SC(C)=N2)C2=C1 BFZKMNSQCNVFGM-UCEYFQQTSA-N 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229930189037 Trapoxin Natural products 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 235000010726 Vigna sinensis Nutrition 0.000 description 1
- 244000042314 Vigna unguiculata Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- RTJVUHUGTUDWRK-CSLCKUBZSA-N [(2r,4ar,6r,7r,8s,8ar)-6-[[(5s,5ar,8ar,9r)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]d Chemical group COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](OC(=O)COC=4C(=C(F)C(F)=C(F)C=4F)F)[C@@H]4O[C@H](C)OC[C@H]4O3)OC(=O)COC=3C(=C(F)C(F)=C(F)C=3F)F)[C@@H]3[C@@H]2C(OC3)=O)=C1 RTJVUHUGTUDWRK-CSLCKUBZSA-N 0.000 description 1
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(e)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
- CKXIPXAIFMTQCS-LRDUUELOSA-N [2-[(2s,4s)-4-[(2r,3r,4r,5s,6s)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 3-aminopropanoate Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCN)[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@H]1F CKXIPXAIFMTQCS-LRDUUELOSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 108010014659 acetyl-glycyl-valyl-allo-isoleucyl-seryl-glutaminyl-isoleucyl-arginyl-prolyl-cysteinamide Proteins 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960004701 amonafide Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- CIDNKDMVSINJCG-GKXONYSUSA-N annamycin Chemical compound I[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(=O)CO)C1 CIDNKDMVSINJCG-GKXONYSUSA-N 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 229910000410 antimony oxide Inorganic materials 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 229950002465 apaziquone Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- UVJYAKBJSGRTHA-ZCRGAIPPSA-N arglabin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(C)=CC[C@]32O[C@]31C UVJYAKBJSGRTHA-ZCRGAIPPSA-N 0.000 description 1
- UVJYAKBJSGRTHA-UHFFFAOYSA-N arglabin Natural products C1CC2C(=C)C(=O)OC2C2C(C)=CCC32OC31C UVJYAKBJSGRTHA-UHFFFAOYSA-N 0.000 description 1
- GEMDZKRHHVNHLW-UHFFFAOYSA-N argon;carbonic acid Chemical compound [Ar].OC(O)=O GEMDZKRHHVNHLW-UHFFFAOYSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 229950005529 arzoxifene Drugs 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229950001429 batabulin Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229950008356 becatecarin Drugs 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- JSKFWUPVIZYJMR-UDOAKELVSA-N bmy-27557 Chemical compound O=C1N(CCN(CC)CC)C(=O)C(C2=C3[CH]C=CC(Cl)=C3NC2=C23)=C1C2=C1C=CC=C(Cl)[C]1N3[C@@H]1O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]1O JSKFWUPVIZYJMR-UDOAKELVSA-N 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- ONOUHNDXYUJUFY-UHFFFAOYSA-N bromane Chemical compound Br.Br.Br.Br ONOUHNDXYUJUFY-UHFFFAOYSA-N 0.000 description 1
- 229950004271 brostallicin Drugs 0.000 description 1
- RXOVOXFAAGIKDQ-UHFFFAOYSA-N brostallicin Chemical compound C1=C(C(=O)NCCN=C(N)N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3N(C=C(NC(=O)C(Br)=C)C=3)C)C=2)C)=CN1C RXOVOXFAAGIKDQ-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- LFBGZTDKGYEQLH-UHFFFAOYSA-N butan-2-ol;dihydrochloride Chemical compound Cl.Cl.CCC(C)O LFBGZTDKGYEQLH-UHFFFAOYSA-N 0.000 description 1
- HPVVIIKTKWMIGP-UHFFFAOYSA-N butyl 3-(3-butoxy-3-oxopropyl)sulfanylpropanoate Chemical compound CCCCOC(=O)CCSCCC(=O)OCCCC HPVVIIKTKWMIGP-UHFFFAOYSA-N 0.000 description 1
- MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- HEJLNVVAJWXAKQ-UHFFFAOYSA-L calcium hydrogen carbonate dihydrate Chemical compound O.O.C([O-])(O)=O.[Ca+2].C([O-])(O)=O HEJLNVVAJWXAKQ-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 description 1
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229950002826 canertinib Drugs 0.000 description 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
- OJLHWPALWODJPQ-QNWVGRARSA-N canfosfamide Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 OJLHWPALWODJPQ-QNWVGRARSA-N 0.000 description 1
- 229950000772 canfosfamide Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- IQCIQDNWBGEGRL-UHFFFAOYSA-N chembl1614651 Chemical compound O=C1C2=C(O)C=CC(O)=C2N2N=C(CNCCO)C3=CC=C(NCCCN)C1=C32 IQCIQDNWBGEGRL-UHFFFAOYSA-N 0.000 description 1
- QUWFSKKBMDKAHK-SBOJBMMISA-A chembl2103793 Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 QUWFSKKBMDKAHK-SBOJBMMISA-A 0.000 description 1
- ZFVRYNYOPQZKDG-MQMHXKEQSA-N chembl560895 Chemical compound O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1N[C@H]1CC[C@H](O)CC1 ZFVRYNYOPQZKDG-MQMHXKEQSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229950006892 contusugene ladenovec Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- AJEHNBIPLQJTNU-UHFFFAOYSA-N cyanomethyl acetate Chemical compound CC(=O)OCC#N AJEHNBIPLQJTNU-UHFFFAOYSA-N 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 108700025485 deslorelin Proteins 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- GDLPAGOVHZLZEK-JBUFHSOLSA-L disodium;(4s)-4-amino-5-[[(1s)-1-carboxylato-2-(1h-indol-3-yl)ethyl]amino]-5-oxopentanoate Chemical compound [Na+].[Na+].C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC([O-])=O)N)C([O-])=O)=CNC2=C1 GDLPAGOVHZLZEK-JBUFHSOLSA-L 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019305 distearyl thiodipropionate Nutrition 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- NDORGWUNFGHGKU-UHFFFAOYSA-N dodecanoic acid;sodium Chemical compound [Na].CCCCCCCCCCCC(O)=O NDORGWUNFGHGKU-UHFFFAOYSA-N 0.000 description 1
- 229960000413 doxercalciferol Drugs 0.000 description 1
- HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229950001287 edotecarin Drugs 0.000 description 1
- BNFRJXLZYUTIII-UHFFFAOYSA-N efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 description 1
- 229960000925 efaproxiral Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 229950002209 efungumab Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229950002189 enzastaurin Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- SFUZTKOCBRWGRV-UHFFFAOYSA-N ethoxysulfonylmethanesulfonic acid Chemical compound CCOS(=O)(=O)CS(O)(=O)=O SFUZTKOCBRWGRV-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940057975 ethyl citrate Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940093470 ethylene Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229950009429 exatecan Drugs 0.000 description 1
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 229950000484 exisulind Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229950011325 galarubicin Drugs 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- UIVFUQKYVFCEKJ-OPTOVBNMSA-N gimatecan Chemical compound C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 description 1
- 229950009073 gimatecan Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229950011595 glufosfamide Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- QSGDGGWTDYSGCY-UHFFFAOYSA-N hexadecaneperoxoic acid Chemical class CCCCCCCCCCCCCCCC(=O)OO QSGDGGWTDYSGCY-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 108700020746 histrelin Proteins 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 229950000340 laromustine Drugs 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229950006761 lexacalcitol Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- 229950001750 lonafarnib Drugs 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229950000547 mafosfamide Drugs 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229950002736 marizomib Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- QXXDTQJIPIKKGF-UHFFFAOYSA-N methanesulfonamide;dihydrochloride Chemical compound Cl.Cl.CS(N)(=O)=O QXXDTQJIPIKKGF-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- LKVXTWZTGPYMLV-UHFFFAOYSA-N methoxysulfonothioylmethanesulfonic acid Chemical compound COS(=O)(=S)CS(=O)(=O)O LKVXTWZTGPYMLV-UHFFFAOYSA-N 0.000 description 1
- UIHPNZDZCOEZEN-YFKPBYRVSA-N methyl (2s)-2-amino-4-methylsulfanylbutanoate Chemical compound COC(=O)[C@@H](N)CCSC UIHPNZDZCOEZEN-YFKPBYRVSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- JFOHFDSMPQIOES-UHFFFAOYSA-N motexafin Chemical compound C1=NC2=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C2N=CC(C(=C2CCCO)C)=NC2=CC(C(CC)=C2CC)=NC2=CC2=C(CCCO)C(C)=C1N2 JFOHFDSMPQIOES-UHFFFAOYSA-N 0.000 description 1
- 229950011637 motexafin Drugs 0.000 description 1
- ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- ISGGVCWFTPTHIX-UHFFFAOYSA-N n'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1CC(O)CONC(=N)C1=CC=CN=C1 ISGGVCWFTPTHIX-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NMWIVJZXSUJBJN-UHFFFAOYSA-N n-decyl-n-octylaniline Chemical compound CCCCCCCCCCN(CCCCCCCC)C1=CC=CC=C1 NMWIVJZXSUJBJN-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- WQZPXLIPGULRSR-UHFFFAOYSA-N n-methylsulfanylpropan-1-amine Chemical compound CCCNSC WQZPXLIPGULRSR-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 101150009274 nhr-1 gene Proteins 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- CNHRNMLCYGFITG-UHFFFAOYSA-A niobium(5+);pentaphosphate Chemical compound [Nb+5].[Nb+5].[Nb+5].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O CNHRNMLCYGFITG-UHFFFAOYSA-A 0.000 description 1
- LAZVTKQYCZFNSZ-UHFFFAOYSA-N nitro formate Chemical compound [O-][N+](=O)OC=O LAZVTKQYCZFNSZ-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229950000891 nolatrexed Drugs 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- WRDMVWDLJLMECM-UHFFFAOYSA-N o-methyl 2-methylpropanethioate Chemical compound COC(=S)C(C)C WRDMVWDLJLMECM-UHFFFAOYSA-N 0.000 description 1
- 229950006584 obatoclax Drugs 0.000 description 1
- GLSRRBHRRXRHAR-UHFFFAOYSA-N octadecyl thiocyanate Chemical compound CCCCCCCCCCCCCCCCCCSC#N GLSRRBHRRXRHAR-UHFFFAOYSA-N 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950003600 ombrabulin Drugs 0.000 description 1
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- VTRUBDSFZJNXHI-UHFFFAOYSA-N oxoantimony Chemical compound [Sb]=O VTRUBDSFZJNXHI-UHFFFAOYSA-N 0.000 description 1
- 229960002239 paclitaxel poliglumex Drugs 0.000 description 1
- 108700027936 paclitaxel poliglumex Proteins 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229950003819 pelitrexol Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229960004403 pixantrone Drugs 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QWJFBNRPVIHFSQ-UHFFFAOYSA-N propan-1-ol;dihydrochloride Chemical compound Cl.Cl.CCCO QWJFBNRPVIHFSQ-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N purine-6-thione Natural products S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 229950007649 ranpirnase Drugs 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 229960005567 rebeccamycin Drugs 0.000 description 1
- INSACQSBHKIWNS-QZQSLCQPSA-N rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 1
- 229950005950 rebimastat Drugs 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- OAKGNIRUXAZDQF-TXHRRWQRSA-N retaspimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OAKGNIRUXAZDQF-TXHRRWQRSA-N 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950009921 seocalcitol Drugs 0.000 description 1
- LVLLALCJVJNGQQ-ZCPUWASBSA-N seocalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C/C=C1/C[C@H](O)C[C@@H](O)C1=C LVLLALCJVJNGQQ-ZCPUWASBSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960005441 sevelamer carbonate Drugs 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 239000010454 slate Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- CBXWGGFGZDVPNV-UHFFFAOYSA-N so4-so4 Chemical compound OS(O)(=O)=O.OS(O)(=O)=O CBXWGGFGZDVPNV-UHFFFAOYSA-N 0.000 description 1
- NGIYLSFJGRLEMI-MHTUOZSYSA-M sodium 2-[[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(2R,3R,4R,5R)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethyl [(2R)-2,3-di(hexadecanoyloxy)propyl] phosphate hydrate Chemical compound O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC NGIYLSFJGRLEMI-MHTUOZSYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- URLJMZWTXZTZRR-UHFFFAOYSA-N sodium myristyl sulfate Chemical compound CCCCCCCCCCCCCCOS(O)(=O)=O URLJMZWTXZTZRR-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- NSFFYSQTVOCNLX-JKIHJDPOSA-M sodium;[(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecyl phosphate;hydrate Chemical compound O.[Na+].O[C@H]1[C@H](O)[C@@H](COP([O-])(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 NSFFYSQTVOCNLX-JKIHJDPOSA-M 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MVGSNCBCUWPVDA-MFOYZWKCSA-N sulindac sulfone Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)(=O)=O)C=C1 MVGSNCBCUWPVDA-MFOYZWKCSA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229950003999 tafluposide Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- 229960003102 tasonermin Drugs 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 229950001699 teceleukin Drugs 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LVEOKSIILWWVEO-UHFFFAOYSA-N tetradecyl 3-(3-oxo-3-tetradecoxypropyl)sulfanylpropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCC LVEOKSIILWWVEO-UHFFFAOYSA-N 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- JOUDBUYBGJYFFP-FOCLMDBBSA-N thioindigo Chemical compound S\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2S1 JOUDBUYBGJYFFP-FOCLMDBBSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical class CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 229960005526 triapine Drugs 0.000 description 1
- NTPUDNWPFKMFHO-UHFFFAOYSA-H tricalcium tricarbonate Chemical compound [Ca++].[Ca++].[Ca++].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NTPUDNWPFKMFHO-UHFFFAOYSA-H 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XWNXEWLCHSLQOI-UHFFFAOYSA-K trisodium;triacetate Chemical compound [Na+].[Na+].[Na+].CC([O-])=O.CC([O-])=O.CC([O-])=O XWNXEWLCHSLQOI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229950011257 veliparib Drugs 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- ZPUHVPYXSITYDI-HEUWMMRCSA-N xyotax Chemical compound OC(=O)[C@@H](N)CCC(O)=O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 ZPUHVPYXSITYDI-HEUWMMRCSA-N 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Description
201041882 w 六、發明說明: 【發明所屬之技術領域】 本發明係關於一種促凋亡劑ABT-263,及使用其於治療 以抗〉周亡Bcl-2家族蛋白之過度表達爲特徵的疾病之方 法。更特定言之’本發明係關於一種ABT-263之新穎鹽及 • 其諸如作爲製備用於將ABT-263投與至有需要之個體的醫 藥組合物之活性醫藥成分(API)之固態形式。 本申請案主張2009年4月30曰申請之美國臨時申請案第 ◎ 61/174,274號之優先權。 前後參照包含有關於本發明之主題之以下共申請之美國 申。月案.名為「Lipid formulation of apoptosis promoter」 之第12/一,一號,其主張2009年4月30曰申請之美國臨時 申請案第61/174,245號之優先權;名為「stabilized lipid formulation of apoptosis promoter」之第 12/_,_號,其 主張2009年4月30日申請之美國臨時申請案第61/174 299號 q 及2009年12月22日申請之第61/289,254號之優先權;名為 「Solid oral formulation of ABT-263」之第 12/_,_號, 其主張2009年4月30日申請之美國臨時申請案第61/174 318 - 號之優先權;及名為「Formulation for oral administration , of apoptosis promoter」之第12/一,一號,其主張以上參考 之美國臨時申請案第61/174,274號、第61/174,299號、第 61/174,318號及第61/289,254號、及2009年6月8日申請之第 61/1 85,105號、2009年6月 8 日申請之第 61/185,130號、2009 年6月18曰申請之第61/218,281號、及2009年12月22曰申請 147960.doc 201041882 之第61/289,289號之優先權。 以上每一申請案之整篇揭示内容係以引用的方式併入文 中。 【先前技術】 凋亡之逃避爲癌症之特徵(Hanahan & Weinberg Cell 100:57-70)。癌細胞必須克服藉由諸如DNA損傷、致 癌因子活化、異常細胞週期進展及引起正常細胞凋亡之惡 劣微環境的細胞應激之連續轟擊。癌細胞逃避凋亡之一主 要方式係藉由上調Bcl-2家族之抗〉周亡蛋白。 佔據Bcl-2蛋白之BH3鍵結溝之化合物已由例如Bnmck〇 等人.(2007) J. Med. Chem· 50:641-662闡述。此等化合物 包含N_(4_(4_((4’_氯_(1,Γ_聯苯)1基)甲基)派嗓小基)苯甲 醯基)-4-(((叫3-(二甲胺基)小((苯基硫基)甲基)丙基)胺 基)-3-硝基苯-磺醯胺,另稱爲ΑΒΤ_737,其具有下式:
ΑΒΤ-73 7於高親和性(<1 ηΜ)下結合至Bcl_2家族(特定言 之Bcl-2、Bcl-XL及Bcl-w)蛋白。其對小細胞肺癌(SCLC)及 147960.doc 201041882 淋巴惡性腫瘤顯示單製劑活性,且加強其他化療劑之促〉周 亡作用。ABT-73 7及相關化合物,及製造此等化合物之方 法係揭示於Bruncko等人之美國專利申請公開案第 2007/0072860號中。 近日’已識別又一系列具高親和性結合至Bci_2家族蛋 白之化合物。此等化合物及製備其等之方法係揭示於 Bruncko等人之美國專利申請公開案第2〇〇7/〇〇27135號中 0 (文中「135公開案」),其全文係以引用的方式併入,且 可自其等結構式得出結構上與ABT-737相關。 I35公開案中認定爲「實例i」之化合物爲n_(4_(4_((2_ (4-氯苯基)-5,5-二甲基環己_丨_烯―卜基)甲基)哌嗪“·基) 苯曱醯基)-4-((( lR)-3-(嗎啉基)-1-((苯基硫基)甲基)丙 基)胺基-3-((二氟甲基)磺醯基)苯磺醯胺,另稱爲ABT_ 263。此化合物之分子量爲974 6 g/m〇1且具有下式:
•135公開案指出文中揭示之特定化合物可呈酸加成鹽、 鹼加成鹽或兩性離子。此等化合物之酸加成鹽包含醋酸 147960.doc 201041882 鹽、己二酸鹽、藻酸鹽、碳酸氫鹽、檸檬酸鹽、天冬胺酸 鹽 '苯甲酸鹽、苯磺酸鹽、硫酸氫鹽、丁酸鹽、樟腦酸 鹽、樟腦續酸鹽、雙葡萄醣酸鹽、甲酸鹽、富馬酸鹽、甘 油磷酸鹽、榖胺酸鹽、半硫酸鹽、庚酸鹽、己酸酯、鹽酸 鹽、氫溴酸鹽、氫碘酸鹽、乳糖酸鹽、乳酸鹽、馬來酸 鹽、均三曱苯磺酸鹽、曱磺酸鹽、萘磺酸鹽、烟鹼酸鹽、 草酸鹽、雙羥萘酸鹽、果膠酸鹽、過硫酸鹽、墻酸鹽、苦 味酸鹽、丙酸鹽、丁二酸鹽、酒石酸鹽、硫氰酸鹽、三氯 醋酸鹽、三氟醋酸鹽、對曱苯磺酸鹽及十一烧酸鹽。 需要改良療法之一特別種類疾病為非霍奇金氏淋巴瘤 (NHL)。NHL·爲美國第六種最常見的新型癌症且主要發生 於60-70歲患者。NHL非單一疾病而為一族相關疾病,該 專疾病係基於包含臨床特徵及組織學之多個特徵而分類。 一種分類方法將不同組織學亞型分爲主要兩類,該方法 係根據疾病之自然史’即’疾病是否係無痛性或侵襲性。 通常,無痛性亞型生長緩慢且通常不可治愈,而侵襲性亞 型生長迅速且可能治愈。滤泡性淋巴瘤為最常見的無痛性 亞型’且彌漫大細胞淋巴瘤為最常見的侵襲性亞型。致癌 蛋白Bcl-2最初係於非霍奇金氏(H〇dgkin,s)B-細胞淋巴瘤中 闡述。 濾泡性淋巴瘤之治療通常係由基於生物學之化學療法或 組合化學療法組成。常使用藉由利妥西單抗(rhuximab)、 環填酿胺、多柔比星(doxorubicin)、長春新驗(vincristine) 及强的松(R-CHOP)之組合療法,如藉由利妥西單抗、環 147960.doc 201041882 璘醯胺、長春新鹼及强的松(RCVP)之組合療法。亦使用藉 由利妥西單抗(靶向CD20,於B -細胞表面上均勻表達之磷 蛋白)或氟達拉濱(fludarabine)之單劑療法。向化學療法方 案添加利妥西單抗可改良反應率及增加無疾病進展之存活 率〇 放射免疫治療劑,高劑量化學療法及幹細胞移植可用於 治療難治性或復發性非霍奇金氏淋巴瘤。目前,未批准一 〇 可治愈之治療方案,且目前方針推薦患者於臨床試驗期間 治療,即使於一線治療期間。 患有侵襲性大B -細胞淋巴瘤的患者之一線治療通常係 由利妥西單抗、環磷醯胺、多柔比星、長春新鹼及强的松 (R-CHOP),或劑量經調整之依託泊苷(et〇p〇side)、强的 松、長春新鹼、環磷醯胺、多柔比星及利妥西單抗(DA_ EPOCH-R)組成。 大多數淋巴瘤起初對此等療法中任一者產生反應,但腫 〇 瘤一般會復發且最終變為難治型。隨著患者接受療法的次 數增加’疾病變得更抗化學療法。對一線療法之平均反應 為約75%,對二線為60%,對三線為50%,對四線療法為 約35-40%。於多次復發治療中對單劑之反應率接近2〇%。 此被認爲係陽性且有必要進一步研究。 目刖的化療劑係猎由多種機理來引起〉周亡進而得到其等 之抗癌抗菌素反應。但是,許多腫瘤最終對此等藥劑產生 抗性。於短期幸存者體外及近期之體内試驗中顯示Bcl2 及Bcl-XL抗化療性。此表明如果可發展目的在於抑制Bd_2 147960.doc 201041882 及BcI-Xl功能之經改良的療法,則可成功地克服此抗化療 性。 【發明内容】 化合物ABT-263當根據’ 13 5公開案之實例1製備時,係以 不大適宜用於下游調配物之活性醫藥成分(Αρι)的非晶型 玻璃狀固體形式回收。本發明現已製備一種新穎之abT_ 263雙-酸加成鹽,其係呈適宜作爲多種型態調配物之Αρι 之多種固態晶型,包含API連同賦形劑一起呈微粒形式之 劑型’諸如呈可經口遞送之錠劑或膠囊形式者。且,已發 現包含新穎鹽類之醫藥組合物顯示至少相當於(且有時優 於)2 mg/ml含ABT-263游離驗之於由peg-400與DMSO以 9 . 1重量比組成之載劑中之溶液的經口生物利用率,此係 記載於」35公開案中。 於一實施例中,本發明提供Ν_(4·(4_((2_(4_氣苯基)·5,5_ 一曱基-1-%:己_1_烯_丨_基)甲基)哌嗪基)苯甲醯基)_4_ (((lR)-3-(嗎啉_4-基苯基硫)甲基)丙基)胺基_3 ((三氟 甲基)磺醯基)笨磺醯胺雙鹽酸鹽(ABτ_263雙_HC1)。 於又一實施例中’本發明提供特徵如本文之Abt-263雙-HC1晶型I。 於再又一實施例中,本發明提供特徵如本文之ABT-263 雙-HC1晶型Π。 於另又一實施例中,本發明提供多種Abt-263雙-HC1之 /合η丨化日日型,包含乙醇、丨_丙醇、2·丙醇、2_丁醇、第三 丁醇确'基甲烷、乙腈、丙腈、甲酸乙酯、乙酸甲酯、乙 147960.doc 201041882 酸乙酯、乙酸異丙酯、丙酮、2-丁酮(甲基乙基酮、 MEK)、甲基異丙酮、ι,4-二噁烷、苯、甲苯及丁基醚溶劑 化物。 於再又一實施例中,本發明提供一種製備ABT-263雙-HC1晶型I之方法’其包含脫去ABT-263雙-HC1之乙醇、 丙醇、2-丙酵、2-丁醇、第三丁醇、乙腈、丙腈、甲酸乙 酯、乙酸甲酯、乙酸乙酯、乙酸異丙酯、丙酮、甲基異丙 ❹ 酮、1,4·二噁烷、苯、曱苯及丁基醚溶劑化物形式之溶 劑。 於再又一實施例中,本發明提供一種製備ABT_263雙_ HC1晶型π之方法,其包含脫去ABT 263,_hc12Mek溶劑 化物形式之溶劑。 於再又一實施例中,本發明提供一種包含ABT_263雙_ HC1及一或多種醫藥上可接受之賦形劑的醫藥組合物。 於另又-實施例巾’本發明提m療以抗〉周亡Bci· 〇 2家族蛋白之凋亡功能紊亂及/或過度表達爲特徵的疾病之 方法,其包含將治療有效量之ABT_263雙_Hcm含ΑΒΤ· 263雙-HC1及-或多種醫藥上可接受的賦形劑之醫藥組合 &投與至患有該疾病之個體。此疾病之實例包含多腫贊瘤 纟疾病,包含癌症。根據本發明方法可治療之—具體癌症 實例為非霍奇金氏淋巴瘤。根據本發明方法可治療的另一 具體癌症之實例爲慢性淋巴細胞性白血病。根據本發明方
法"T /台療的又另一具體癌症之實彳@m A 只列爲急性淋巴細胞性白血 病’例如於兒科患者。 147960.doc -9- 201041882 又另提供一種方法,其用於維持癌症患者血流中之 ABT-263及/或—或多種其代謝物之治療有效血漿濃度,例 如患有非霍奇金氏淋巴瘤、慢性淋巴細胞性白血病或急性 淋巴細胞性白金病之患者,其包含將包含ABT-263雙-HC1 及一或多種醫藥上可接受的賦形劑之醫藥組合物投與至該 患者’其劑量量相當於約50至約5〇〇 mg ABT-263/天,平 均投藥間隔為約3小時至約7天。 包含以上提供之實施例之更多特定態樣的本發明之其他 實施例將從以下具體説明中瞭解或輕易自其中顯現。 【實施方式】 ABT-263具有至少兩個可質子化的氮原子且因此可與一 種以上之例如每當量化合物約1.2至約2,約1.5至約2或約 1·8至約2當量之酸形成酸加成鹽。舉例而言,可形成的雙 鹽包含醋酸鹽、己二酸鹽、藻酸鹽、碳酸氫鹽、檸檬酸 鹽、天冬胺酸鹽、苯甲酸鹽、苯磺酸鹽、硫酸氫鹽、丁酸 鹽、樟腦酸鹽、樟腦磺酸鹽、雙葡萄醣酸鹽、甲酸鹽、富 馬酸鹽、甘油磷酸鹽、榖胺酸鹽、半硫酸鹽、庚酸鹽、己 酸酯' 鹽酸鹽、氫溴酸鹽、氫碘酸鹽、乳糖酸鹽、乳酸 鹽、馬來酸鹽、均三甲苯磺酸鹽、曱磺酸鹽、萘續酸鹽、 烟鹼酸鹽、草酸鹽、雙羥萘酸鹽 '果膠酸鹽、過硫酸鹽、 磷酸鹽、苦味酸鹽、丙酸鹽、丁二酸鹽、酒石酸鹽、硫氰 酸鹽、三氣醋酸鹽、三氟醋酸鹽、對曱苯磺酸鹽及十一烷 酸鹽之雙鹽,諸如雙-鹽酸鹽(雙-HC1)及雙-氫溴酸鹽(雙-HBr)。 147960.doc 10- 201041882 分子量為1047.5 g/mol之ABT-263雙-HCl,可由以下結 構式表不·
ABT-263雙-HC1可以固態形式存在且可以如下文所述之 形式分離。作爲API而言,ABT-263雙-HC1應實質上係純 的,例如純度至少約90%,至少約95°/。,至少約96%,至 少約97%,至少約98%,或至少約99重量%。固態形式之 ABT-263雙-HC1可為晶型或非晶型。ABT-263雙-HC1亦可 以於適宜助溶介質中之增溶形式存在,諸如下文所述。 ABT-263雙-HC1(以游離鹼等效物表示)於此介質中之濃度 可諸如爲至少約0.1 mg/ml、至少約0.2 mg/ml、至少約0.5 mg/ml、至少約1 mg/ml、至少約2 mg/ml或至少約5 mg/ml,高至於此介質之溶解限值,諸如高至約500 mg/ml,高至約400 mg/ml,高至約300 mg/ml,高至約200 mg/ml或高至約 100 mg/ml。 ABT-263雙-HC1可藉由包含將ABT-263游離鹼與2莫耳鹽 酸(HC1)於適宜介質中反應之任意方法製得。為方便使 147960.doc -11 - 201041882 用,術語「游離鹼」係指ABT-263母體化合物,而認爲母 體化合物嚴格說來係爲兩性離子型且因此並非總是表現得 如同實際之鹼。 ΑΒΤ-263游離鹼可如上述美國專利申請公開案第 2007/0027135號之實例1中所述製備,該公開案之所有揭 示内容係以引用的方式併入文中。 製備ΑΒΤ-263雙-HC1之具體方法係如下闡述。 本方法之第一階段包含以下反應以製得ΑΒΤ-263母體化 合物:
、0
,Ν、 X) 1)DMAP (2.63 當量) EDCI (1.56當量) CH2C12 (7 vol.) 30°C, 48 h 2) DMEDA 室溫,2h
步驟1 步驟2 ΑΒΤ-263 C26H31CIN2O2 C21H26F3N3O5S3 C47H55CIF3N5O6S3 莫耳量:438.99 莫耳量:553.64 莫耳量:974.61 其中「步驟1」及「步驟2」產物為分別根據’135公開案 之實例1Μ及II而製得的中間產物。「DMAP」為Ν,Ν-二甲 胺基-吡啶。「EDCI」為1-(3-二曱胺基丙基)-3-乙基碳二 醯亞胺。「DMEDA」為Ν,Ν-二甲基乙二胺。ΑΒΤ-263母體 化合物並非自反應混合物以固體産物形式回收。 更特定言之,將步驟2產物(13.3 kg,20.46 mol)、步驟1 147960.doc -12- 201041882 產物(9·9 kg, 22.5 mol)、DMAP(6.6 kg,53.81 mol)及 EDCI 鹽酸鹽(6.12 kg,31.92 mol)注入反應器。然後注入二氯曱 烷(126 kg),且於30°C下加熱所得反應混合物直至反應完 全(約24小時;殘餘步驟2產物<0.3%)。可藉由逆相HPLC 監測該反應。 使該反應混合物冷却至室溫,且藉由添加DMEDA(1.62 kg,18.41 mol)將過量活化酸驟冷。 使反應混合物蒸餾至體積約48升並注入8.0 kg水及150 kg乙酸乙酯(EtOAc)。使該混合物蒸餾至體積爲90升並另 注入8.0 kg水及150 kg EtOAc。使該混合物蒸餾至體積爲 115升並注入200 kg之10%乙酸+0.75%氯化鈉溶液及100 kg EtOAc。混合反應器内容物並分離。藉由200 kg之10%乙 酸+0.75%氯化鈉溶液、267 kg之25% K2HP〇4溶液及242 kg 之pH 7緩衝溶液沖洗有機層。 將有機層濃縮至約48升,與兩份EtOAc(180 kg, 180 kg) 一起進行追加蒸餾,每次皆濃縮至約48升。另注入 EtOAc(85 kg),且藉由費歇爾(Karl Fischer)滴定測量含水 量 ° 利用乙醇(EtOH, 62 kg)稀釋所得的EtOAc溶液且經聚丙 烯0.5 μπι濾器精濾至乾淨的反應器中,利用EtOAc(20 kg) 作為潤洗劑。於一單獨便攜式反應器中,製備HC1(4.3 kg) 之EtOH(80 kg)溶液且經一單獨的新慮器精遽並存入反應 器。以EtOH(10 kg)進行清洗。有機溶液之精濾自最終提 取物分離出殘餘磷酸鹽。需使用潔淨的濾器及容器以避免 147960.doc -13- 201041882 中和HC卜 將所得溶液濃縮至約245升且維持此體積,同時另追加 EtOH(497 kg)。藉由HPLC進行分析以確定是否另注入 EtOH以達到結晶ABT-263雙-HC1所需之約20體積。 將產物溶液加熱至45°C,且添加ABT-263雙-HC1晶種 (150 g)之EtOH(l kg)漿液。65 rpm下授拌6小時後,1小時 内將漿液冷却至20°C且另混合36小時。分析濾液以指出結 晶完全^ 將該漿液濾入利用聚丙烯濾器墊之濾器-乾燥器。利用 EtOH(2x80 kg)清洗固體。以漿液形式於攪拌下非真空施 用清洗液(每次接觸時間1 5-25分鐘)且隨後藉由真空過濾進 行移除。對所得濕濾餅進行抽樣分析雜質,以確定再結晶 是否必要。 於50°C下,氮氣中真空乾燥固體8天並進行溫和攪拌(最 先8小時為每小時攪拌5分鐘,然後每8小時攪拌5分鐘)。 乾燥後樣品之分析表明乾燥是完全的(殘留EtOH<0.05%)。 進行上述方法時,得到的白色固體產物產量為17.4 kg (81.0% HPLC峰面積產率,99.72%效能)。 本方法之產物為如以下詳細闡述之ABT-263雙-HC1晶型 I,藉由脫去乙醇溶劑化物溶劑而製得實質上無溶劑之晶 型。該産物已於多種醫藥組合物(調配物)之下游製造中作 爲 API。 如下述自API製備ABT-263雙-HC1之溶劑化物。 將測得量(重量%)之如上製得的ABT-263雙-HC1懸浮於 147960.doc -14· 201041882 0.5 ml如表1中所列的單獨每一溶劑中。於室溫下避光攪拌 該等懸浮液。所得溶劑化物藉由粉末X-射線繞射(PXRD) 決定特徵。 利用配有彎曲位置靈敏探測器及平行光束光學裝置之 G3000繞射儀(Inel Corp·,Artenay,法國)收集 PXRD數據。 利用銅陽極管(1.5 kW微聚焦)於40 kV及30 mA下操作該繞 射儀。入射光束鍺單色器提供單色輻射。利用衰減直射光 束以一度間隔校準該繞射儀。利用矽粉行位置參照標準 (NIST 64〇c)對此校準進行核實。利用Symphonix軟體(Inel Corp·, Artenay,法國)電腦控制該設備並利用Jade軟體(6.5 版,Materials Data, Inc.,Livermore, CA)分析數據。將樣品 負載於鋁樣品固持器上且與以玻璃載片勻平。 表1.用於製備ABT-263雙-HC丨溶劑化物晶體之溶劑 溶劑 化合物重量(mg) 乙醇 274.5 2-丙醇 249.8 第三丁醇 255.8 1-丙醇 259.6 2-丁醇 260.1 石肖基曱烧 284.5 乙腈 290.7 丙腈 295.5 乙酸乙酯 300.6 乙酸異丙酯 301.2 甲酸乙酯 293.3 乙酸甲酯 256.5 丙酮 250.4 2-丁酮(MEK) 252.8 甲基異丙酮 255.5 147960.doc -15- 201041882 溶劑 化合物重量(mg) 1,4-二噁烧 262.4 苯 250.1 甲苯 290.2 丁基醚 289.6 製得一些溶劑化物之單晶體以進行結晶分析。 為製得丙腈溶劑化物之單晶體,於60°C下,將如上製備 的ABT-263雙-HC1懸浮於丙腈中。利用針筒式過濾器過濾 該懸浮液,且將濾液轉移至一新小瓶中。將該小瓶置於己 烷室中。一週後觀察單晶體。表2中顯示丙腈溶劑化物之 結晶數據。 表2. ABT-263雙-HC1丙腈溶劑化物之結晶資料 點陣類型 三斜晶 晶格群 Ρ 1 晶胞長度a 13.975 A 晶胞長度b 16.988 A 晶胞長度C 17.850 A 晶胞角度α 101.816° 晶胞角度β 105.892° 晶胞角度γ 112.258° 晶胞體積 3538.28 A3 Ζ 2 為製備硝基曱烷溶劑化物之單晶體,於60°C下,將如上 製備的ABT-263雙-HC1懸浮於硝基甲烷中。利用針筒式過 濾器過濾該懸浮液,且將濾液轉至一新小瓶中。將該小瓶 置於2- 丁酮室中。一週後觀察單晶體。表3中列出硝基甲 烧溶劑化物之結晶數據。 147960.doc -16- 201041882 表3· ABT-263雙-HC1硝基甲烷溶劑化物之結晶資料 點陣類型 單斜晶 晶格群 C2 晶胞長度a 31.500 A 晶胞長度b 13.812A 晶胞長度c 30.764 A 晶胞角度α 90.000° 晶胞角度β 116.205° 晶胞角度γ 90.000° 晶胞體積 12009.1 A3 Ζ 8 為製備乙腈溶劑化物之單晶體,於接近其溶解度限值之 高溫下,將如上製備的ABT-263雙-HC1溶於1 : 99體積%之 水/乙腈中。然後,將所得清液自然地冷卻至室溫。若干 天後觀察單晶體。表4中列出乙腈溶劑化物之結晶數據。 表4. ABT-263雙-HC丨乙腈溶劑化物之結晶資料 點陣類型 三斜晶 晶格群 Ρ 1 晶胞長度a 13.799 A 晶胞長度b 15.267 A 晶胞長度C 15.971 A 晶胞角度α 112.862° 晶胞角度β 108.978° 晶胞角度γ 96.294° 晶胞體積 2822.21 A3 Ζ 2 表5-23中列出各自溶劑化物之PXRD峰。峰位置一般為 ±0.2 °2Θ。就丙腈、硝基甲烧及乙腈溶劑化物而言,由單 晶結構計算PXRD峰。 147960.doc 201041882 表5. PXRD峰表:ΑΒΤ-263雙-HC1乙醇溶劑化物 峰位置Ρ2Θ、 相對強度 5.7 1.3 6.8 53.3 7.1 3.3 7.9 2.5 --9-6 6.5 12.3 5.6 ——-J3.6 4.5 ——-J5.8 9.3 — 18.4 10.2 18.6 18.6 _ ... 19.5 13.7 _ 19.8 81.5 — 20.0 100.0 —~ 表6· PXRD峰表:ABT-263雙-HC1 2-丙醇溶劑化物 峰位詈(。20) 相對強度 6.5 11.7 ________7.0 56.8 2.5 5.0 ——-i6.2 7.4 " ~ --—.___17.1 4.8 4.5 __18.2 100.0 ——-J8.5 96.1 ——_J8.7 38.9 19ή 6.7 ^ — 表7· PXRD峰表:ABT_263雙·第三τ醇溶劑化物 _ 峰位晋 相對強度
147960.doc •18· 201041882 峰位置ί°2θ) 相對強度 - 11.1 6.8 11.4 6.8 12.2 5.6 13.7 5.5 15.9 14.7 - 17.6 10.1 18.4 100.0 表8· PXRD峰表:ΑΒΤ-263雙-HCl 1-丙醇溶劑化物 峰位置Ρ2Θ) 相對強度 6.6 89.9 7.1 3.7 7.8 3.2 9.5 13.0 12.1 5.7 13.5 5.5 15.4 16.9 18.1 9.5 18.5 20.3 19.2 17.0 19.5 100.0 21.5 14.2
表9. PXRD峰表:ΑΒΤ-263雙-HCl 2-丁醇溶劑化物 峰位置(°2Θ) 相對強度 6.8 1⑻.0 7.9 1.2 9.8 11.1 12.2 3.2 13.6 6.0 15.8 10.0 18.2 9.1 18.5 16.6 19.8 80.1 20.0 88.4 147960.doc -19- 201041882 表10.PXRD峰表:ABT-263雙_HC丨硝基甲烷溶劑化物(由 晶體結構計算) 峰面積(°2β) 相對強度 3.2 1.4 6.2 60.1 6.4 100.0 6.7 12.0 7.1 11.9 8.4 57.0 11.9 26.4 _ 13.4 14.5 14.0 9.9 15.9 17.4 一 17.1 12.4 — 17.4 38.4 — 18.6 32.4 — 18.7 35.2 —20.1 38.4 ' 21.0 21.3 21.7 17.8 表11. PXRD峰表:ABT_263雙_HC丨乙腈溶劑化物(由晶體 結構計算) 峰位晋 相對強度 ________ 6.5 92.7 ——-6.8 59.5 ~ ~__7.0 29.2 __J7.4 2.3 ~ —__8.2 50.4 -~_9.2 6.9 ~ _11.1 12.8 ___12.1 12.4 — —__13.1 17.4 14.1 16.6 147960.doc -20- 201041882 峰位置(°2Θ) 相對¥5 _ 15.4 25.6^ — 15.9 26.7 ~~~ — 17.1 46.Γ~^ 17.8 100Ό 18.1 1 8L8 — 18.4 — ------ 56.9 —一 19.1 ' '--— 13.3 20.0 193~~~— 20.6 23.2 〜 一 21.2 Ί5?Γ — 21.7 ηΥ~~~~~~ 表12· PXRD峰表:ΑΒΤ-263雙-HC丨丙腈溶劑化物(由晶體
結構計算) 十位置(°2Θ) 相對強度 5.5 100.0 — 6.0 3.0 6.6 9.3 ---7.1 17.0 — 7.3 14.1 _8-4 1.0 9.4 3.4 — 12.7 4.9 14.2 4.8 14.6 4.5 ___15.7 6.3 __18.0 6.6 —— 18.3 7.8 20.fi 4.6 表13. PXRD峰表:αβτ·263雙-HC1乙酸乙酯溶劑化物 -t 位置(°2Θ) 相對強度 --^6.7 100.0 3.2 ___8.0 6.4 147960.doc -21- 201041882 —嗶位置(°2Θ、 相對強度 —__9.6 21.9 —___12.4 13.2 —____13.5 7.3 10.3 —15.1 9.2 — 15.8 15.0 ___ 17.3 "" 10.9 _ 18.5 50.1 19.8 — 94.3 —_20.0 97.5 22.1 20.0 24.5 — 11.2 表14. PXRD峰表:ΑΒΤ-263雙-HC1乙酸異丙酯溶劑化物 峰位置(°2Θ) 相對強度 — 6.6 73.3 7.8 2.7 9.5 15.2 12.0 4.8 13.4 5.9 14.7 6.9 15.4 5.0 18.1 15.6 18.4 22.4 19.3 100.0 表15. PXRD峰表:ABT-263雙-HC1曱酸乙酯溶劑化物 峰位置(°2Θ) 相對強度 5.7 1.6 6.8 85.8 7.2 3.8 8.0 4.5 9.7 13.9 12.3 9.7 13.7 8.9 147960.doc -22· 201041882
峰位置(°2Θ) 相對強度 15.9 15.7 18.6 46.9 19.6 18.4 19.9 100.0 22.0 21.7 表16. PXRD峰表:ABT-263雙-HC1乙酸甲酯溶劑化物 峰位置(°2Θ) 相對強度 6.7 23.1 7.0 57.2 8.2 4.0 11.8 10.0 16.3 6.4 16.8 5.5 17.5 3.6 18.1 85 18.3 100.0 18.7 19.1 21.1 19.1 表17· PXRD峰表:ABT-263雙-HC丨丙酮溶劑化物 峰位置(°2Θ) 相對強度 6.9 63.2 8.2 3.4 11.8 5.6 12.1 2.5 16.3 10.7 16.7 9.8 17.8 14.8 18.2 100.0 18.4 63.3 20.8 20.2 21.1 14.1 147960.doc -23- 201041882 表18. PXRD峰表:ABT-263雙-HC1MEK溶劑化物 峰位置(°2Θ) 相對強度 6.2 100.0 8.2 4.3 10.4 6.3 13.1 8.8 17.0 39.1 17.2 38.8 18.3 14.7 18.8 9.4 表19. PXRD峰表:ABT-263雙-HC1甲基異丙酮溶劑化物 峰位置(°2Θ) 相對強度 6.5 100.0 7.8 1.6 9.3 15.9 12.3 6.5 13.3 4.7 14.8 5.3 15.6 5.7 18.0 26.4 18.4 8.1 19.1 50.0 19.5 64.2 表20. PXRD峰表:ABT-263雙-HC丨1,4-二噁烷溶劑化物 峰位置(°2Θ) 相對強度 5.7 100.0 7.0 3.1 7.5 2.9 15.3 6.8 16.0 5.0 17.0 11.4 17.8 5.8 18.4 17.7 147960.doc -24· 201041882 Ο
147960.doc 峰位置i〇2fn 相對強度 18.6 28.6 19.5 32.4 20.4 9.1 21.3 22.1 表21· PXRD峰表:ΑΒΤ-263雙-HC1苯溶舞丨化物 峰位晋 相對強度 5.3 100.0 5.7 53.9 6.5 25.9 6.8 ---- 46.5 7.2 45.6 17.9 --------- 48.1 18.2 80.4 -J8.6 85.7 19.3 12.2 19.6 14.9 20.2 15.3 20.7 15.3 21.0 23.6 21.Ί 21.4 表22. PXRD峰表:ABT-263雙-HC1甲苯溶劑化物 峰位晋 相對強度 5.5 100.0 6.7 — 14.5 7.0 5.9 --L9 4.4 9.3 3.9 10.7 7.2 .14.1 13.5 _ 14.7 8.8 17.8 41.2 18.0 42.0 18.S 17.1 -25- 201041882 峰位置(°2Θ) 相對強度 19.3 36.6 19.8 16.0 表23. PXRD峰表:ABT-263雙-HC1丁基醚溶劑化物 峰位置(°2Θ) 相對強度 6.7 28 7.0 60.6 8.4 9.8 11.8 5.9 12.2 3.5 13.5 5.3 16.5 8.0 16.7 10.8 17.9 39.7 18.4 100.0 20.7 15.4 20.8 17.1 21.2 23.1 脫去大多數溶劑化物(包含1-丙醇、2-丙醇、2-丁醇、第 三丁醇、乙腈、丙腈 '甲酸乙酯、乙酸甲酯、乙酸乙酯、 乙酸異丙酯、丙酮、甲基異丙酮、1,4-二噁烷、苯、甲苯 及丁基醚溶劑化物)之溶劑產生ABT-263雙-HC1之無溶劑晶 型,顯示其PXRD與脫去乙醇溶劑化物之溶劑製得的API相 等。指定該晶型為第I型。圖1顯示ABT-263雙-HC1第I型之 PXRD掃描。表24列出ABT-263雙-HC1第I型之PXRD峰。具 有實質上如文中所示之峰的PXRD圖可用於識別ABT-263 雙-HC1,更特定言之ABT-263雙-HC1第I型。本發明之上下 文中詞語「實質上如所示」意指較所示位置偏離不超過約 0.2。20之峰。應認識到峰之相對强度每次可有些變化,但 147960.doc •26· 201041882 通常而言,峰强度之分級可類似於表24中所示的PXRD圖 分級。 表 24. PXRD 峰表:ABT-263 雙-HC1 第 I型 峰位置(°2Θ) 相對強度 6.8 59.0 7.2 75.9 8.5 14.3 9.3 4.3 11.2 6.5 13.8 15.8 14.0 17.7 14.9 9.5 16.7 17.5 17.5 15.7 18.2 52.2 18.5 100.0 18.7 95.4
ABT-263雙-HC1第I型通常因存在以下PXRD峰中任一個 或更多個,例如任兩個或更多個,任三個或更多個,任四 個或更多個、或所有而與以下之第II型不同:6.8、7.2、 8.5、18.5及 18.7。20,在每一情況下±0.2。20。 脫去ΜΕΚ溶劑化物之溶劑產生ABT-263雙-HC1之無溶劑 晶型,由PXRD顯示其不同於脫去乙醇溶劑化物之溶劑產 生的API之無溶劑晶型。將脫去MEK溶劑化物之溶劑而產 生的此晶型指定為第II型。圖2顯示ABT-263雙-HC1第II型 之PXRD掃描。表25中列出ABT-263雙-HC1第II型之PXRD 峰。具有實質上如文中所示之峰的PXRD圖可用於識別 ABT-263雙-HC1,更特定言之ABT-263雙-HC1第II型。於 147960.doc -27- 201041882 本發明上下文中短語「實質上如所示」意指具有較所示位 置偏離不超過約0.2。20之峰。可認爲峰之相對強度每次可 略微不同,但通常而言,峰強度之分級類似於圖25中所示 的PXRD圖之分級。 表 25. PXRD 峰表:ABT-263 雙-HC1 第 II 型 峰位置(°2Θ) 相對強度 3.7 6.0 7.4 100.0 12.1 5.3 15.6 8.6 16.1 16.2 16.6 21.6 18.3 70.2 19.0 13.4 ABT-263雙-HC1第II型通常而言可因存在以下PXRD峰之 任一者或兩者而與第I型不同:3.7與7.4 °2Θ,在每一情況 下 ±0.2 02θ。 ΑΒΤ-263雙-HC1,諸如第I型、第II型或其等組合,可用 於製備適於對有需要之個體以任意途徑(包含經口)投與之 醫藥組合物。因此,於本發明之若干實施例中,提供一種 含ΑΒΤ-263雙-HC1及一或多種醫藥上可接受的賦形劑之醫 藥組合物。於一實施例中,組合物包含ΑΒΤ-263雙-HC1第I 型。於另一實施例中,組合物包含ΑΒΤ-263雙-HC1第II 型。於又另一實施例中,組合物包含含ΑΒΤ雙-HC1之適宜 載劑系統之溶液。根據此等實施例中任一者,組合物可例 如經口途徑遞送。其他投與途徑非限制性包含非經腸、舌 147960.doc -28- 201041882 下經頻鼻内、經肺、局部、經皮、皮内、經眼、經 耳、經直腸、經陰道'胃内、顱内、滑囊腔内及關節内途 徑。 • 當根據適宜療法,將組合物投與至有需要之個體時,此 等組合物包含量可在治療上有效之八3丁_263雙_]^(::1。劑量 量於文中表示爲游離鹼等效物量,除上下文另有所需。一 般地可以適且頻率(諸如,每天兩次至每週一次)投與之 〇 單位劑量(於每次投與之量)爲約10至約1,000 mg。當投與 頻率為每天一次(q d )時,單位劑量及曰劑量相同。具體 而言,本發明之組合物中ABT_263之單位劑量可為約25至 、·勺1,000 mg更典型地約50至約500 mg,例如約50、約 100、約150、約200、約 250、約300 、約35〇 、約 4〇〇、約 450或約500 mg。當組合物係以不連續劑型(諸如錠劑或膠 囊)製備時,單位劑量可以單劑型或少量(最典型地為〗至約 10個劑型)劑型遞送。 Ο 單位劑量越高,更需選擇調配物中可負載較多API(於此 情況中為ABT-263雙-HC1)之賦形劑。典型地,abt_263 雙-HC1於本發明之調配物中之濃度(表示爲游離鹼等效物) 爲至少約1%,例如,約1%至約5〇重量%,但於特定情況 中,更低及更高濃度可接受或達成。具體而言,於多個實 施例中,ABT-263游離鹼等效物濃度爲調配物之至少約 2/〇 ’例如,約2%至約4〇重量%,諸如約、約1〇%、約 15%、約20%、約25%或約30重量%。 本發明之組合物除API外仍包含一種或多種醫藥上可接 147960.doc •29- 201041882 受的賦形劑。如組合物欲製備成經口投與之固態形式,例 如錠劑或膠囊,其通常包含至少一種或多種固體稀釋劑及 一種或多種固體崩解劑。視需要地,賦形劑進一步包含一 種或多種黏結劑、潤濕劑及/或防磨擦劑(潤滑劑、防黏劑 及/或助流劑)。醫藥組合物中之許多賦形劑具有兩或更多 功能。一特定賦形劑以具有一特定功能之文中特徵,諸如 稀釋劑、崩解劑'黏結劑等,不應理解爲限制為此功能。 關於賦形劑之進一步信息可於標準參照工具中查得,諸如
Handbook of Pharmaceutical Excipients,第三版(Kibbe (2000)版,Washington: American Pharmaceutical Association)。 適宜稀釋劑具體包含乳糖(包含無水乳糖及乳糖—水化 物),乳糖醇;麥芽糖醇;甘露糖醇;山梨糖醇;木糖 醇;葡萄糖及葡萄糖一水化物;果糖;蔗糖及以蔗糖爲主 的稀釋劑,諸如可壓縮糖、糖粉及糖丸;麥芽糖;肌醇; 經水解之穀類固體;澱粉(諸如,玉米澱粉、小麥澱粉、 米澱粉、馬鈴薯澱粉、木薯澱粉等)、澱粉組分,諸如直 鏈澱粉及葡萄糖結合劑、及經改質或經加工之澱粉(諸如 預膠凝澱粉);糊精;纖維素包含粉狀纖維素、微晶纖維 素、矽酸化微晶纖維素、食品級來源的…及非晶型纖維素 及粉狀纖維素、及醋酸纖維素;鈣鹽包含碳酸鈣、碳酸三 鈣、碳酸氫鈣二水合物、碳酸二氫鈣單水合物、硫酸鈣及 粒狀乳酸鈣三水化物;石炭酸鎂;氧化鎂;皂土;高嶺土; 虱化鈉等中之一者或其等組合。此等稀釋劑如存在,—般 總共佔組合物之約5%至約95%,例如約㈣至約㈣,或 147960.doc -30· 201041882 、”勺50/。至約85重量%。所選的一稀釋劑或多種稀釋劑較佳 顯不適宜流動性及錠劑時所需的可壓縮性。 微晶纖維素及矽酸化微晶纖維素爲特別有用的稀釋劑, 且視需要與水溶性稀釋劑(諸如甘露糖醇)組合使用。具體 而言,微晶纖維素或矽酸化微晶纖維素對甘露糖醇之適宜 重量比為約10 : 1至約1 : 1,但超出此範圍之比例於特定 環境中可用。 0 適且的崩解劑包含澱粉(包含預膠凝澱粉及澱粉羥基乙 酸鈉);白土;矽酸鎂鋁;以纖維素為主的崩解劑,諸如 粉狀纖維素、微晶纖維素、甲基纖維素、經低取代之經丙 基纖維素、羧曱基纖維素、羧甲基纖維素鈣、羧曱基纖維 素納及父聯缓甲基纖維素鈉;藻酸鹽;聚維酮;交聯聚維 酮;泊拉可林鉀;膠諸如瓊脂、瓜耳膠、槐豆、刺梧桐、 果膠及兴蓍膠,膠體二氧化石夕等中之一者或其等組合。一 種或多種崩解劑(如存在)一般總共地佔組合物之約〇 2%至 〇 約3〇%,例如約至約2〇%,或約1%至約1〇重量%。 澱粉經基乙酸納爲一特有效之崩解劑,且一般總共地佔 組合物之約至約20%,例如約2%至約15%,或約5%至 約10重量%。 黏結劑或黏著劑爲有效的賦形劑,尤其於組合物爲錠劑 形式時。此等黏結劑及黏著劑應賦予待製鍵的推合物足够 的黏合性以用於標準的加工操作,諸如筛分、潤滑、壓製 及封裝,但仍允許錠劑崩解及組合物於消化時吸收。適宜 的黏結劑及黏著劑包含阿拉伯膠;黃看膠;葡萄糖;聚糊 147960.doc 201041882 :基:包含預膠凝_);明膠;經改質之纖維素(包含 :r :、羧甲基纖維素鈉、羥丙基F基纖維素 ,Μ )、#丙基纖維素m基纖維素及乙基纖維素);、 糊精(包含麥芽糖糊接、, 、 ^ 精),玉米醇溶蛋白;藻酸及藻酸鹽, 諸如藻酸鈉;矽酸鎂铉.白 | . /㈣銘H聚乙二醇(PEG);聚環氧 •元瓜爾膠,夕酶酸類;聚乙婦σ比略咬酮(聚維酮或 PVP) m_K'15 ' K·30 及 Κ-29/32 ;聚丙稀酸(卡波 姆)’·聚甲基丙烯酸醋等中之一者或其等組合。一或多種 之黏結劑及/或黏著劑(如存在)一般總共地佔組合物之約 〇·5%至約25%,例如約1%至約⑽,或約1>5%至約 %。 里 聚維酮及㈣基纖料巾之任—者或組合歧劑調配物 之最爲有效的黏結齊!,且如存在,一般佔組合物之約〇5% 至約15%,例如約1%至約1〇%,或約2%至約8重量0 通常選擇濕潤劑(如存在)以維持藥物與水緊密結合一 種可改良組合物之生物可利用性之狀態。可㈣濕潤劑之 表面活性劑的非限制性實例包含四級銨化合物諸如氯化 苄二甲烴銨、氯化苄乙氧銨及氣化十六烷基吡啶;磺基琥 珀酸二辛酯鈉;聚環氧乙烷烷基苯基醚,諸如壬苯醇醚 9、壬苯醇醚1〇及辛苯聚醇9 ;泊洛沙姆(聚環氧乙烷及聚 氧丙烯嵌段共聚物聚環氧乙烷脂肪酸甘油酯及油類, 諸如聚環氧乙烷(8)辛酸/癸酸單-及雙甘油酯、聚環氧乙烧 (35)1麻油及聚環氧乙烷(40)氫化t麻油;聚環氧乙烧烧 基醚,例如鯨蠟醇聚醚-1 〇、月桂醇醚_4、月桂醇越、 147960.doc •32· 201041882 油醇醚-2、油醇醚_1〇、油酵醚_2〇、硬脂醇醚_2、硬脂醇 Ο
2_1〇、硬脂醇趟-20、硬脂醇醚_10〇及聚環氧乙烷(20)十 六基十八基醚;聚環氧乙烷脂肪酸酯、例如聚環氧乙烷 (2〇)硬脂酸酯、聚環氧乙烷(4〇)硬脂酸酯及聚環氧乙: (〇〇)硬月曰酸S曰’山梨糖醇酐酯,諸如山梨糖醇酐單月桂酸 酯、山梨糖醇酐單油酸醋、山梨糖醇酐單棕櫚酸酯及山梨 糖醇酐單硬脂酸酿;聚環氧乙院山梨糖醇針醋,諸如聚山 梨酸醋20及聚山梨酸賴;丙二醇脂肪酸醋,諸如丙二醇 月桂酸酯;月桂基硫酸鈉;脂肪酸及其鹽,諸如油酸、油 酸鈉及三乙醇胺油酸鹽;脂肪酸甘油酯,諸如單油酸甘油 酯、單硬脂酸甘油酯及棕櫚油硬脂酸甘油酯;烷芳聚醚醇 等中之-者或其等組合。一種或多種潤濕劑(如存在卜般 總共地佔組合物之約〇.1%至約15%,例如約〇2%至約 10% ’或約0.5%至約7重量%。 非離子型表面活性劑’更具體言之泊洛沙姆爲本發明可 用的潤濕劑之實例。具體言之,諸如(plur〇nicTM Fi27)之 泊洛沙姆(如存在)可佔組合物之約〇 1%至約1〇%,例如約 0.2%至約7% ’或約0.5%至約5重量〇/0。 潤滑劑於壓製錠劑調配物期間减少製錠混合物與製錠裝 置之間的摩擦。適宜的潤滑劑包含山荼酸甘油酯;硬脂酸 及其鹽,包含硬脂酸鎂、鈣及鈉;氫化植物油;棕櫚油硬 脂酸甘油酯;滑石;蠟;苯甲酸鈉;乙酸鈉;富馬酸鈉; 富馬酸硬脂鈉;PEGs(諸如,PEG 4000及PEG 6000);泊洛 沙姆;聚乙烯醇;油酸鈉;月桂基硫酸鈉;月桂基硫酸鎂 147960.doc •33- 201041882 等中之-者或其等組合。一種或多種潤滑劑(如存在)一般 總共地佔組合物之約〇 〇5%至約10% 例如約0.1%至約 5%,或約0.2¼至約2重量%。富馬酸 潤滑劑。 ㉟爲-極有效的 防黏劑可減少錠劑調配物對設備表面 黏附。適宜的防 黏劑包含滑石、膠體二氧化矽、澱粉、^ △ 白月女酸、月桂 基硫酸鈉及金屬硬脂酸鹽。一種或多種防黏劑(如存在)一 般總共地佔組合物之約0.05%至約丨〇% 例如約0.1%至約 7%,或約0.2〇/〇至約5重量%。膠體二氧化 円 ^场一取有效防 黏劑。 助流劑改良流動性且减少錠製混合物之餘 〜肝·电。通宜的助 流劑包含膠體二氧化矽、澱粉、粉狀纖維素、月桂美辟酸 鈉、二石夕酸鎮及金屬硬脂酸鹽中之一者或其等組人 戈 多種助流劑(如存在)通常總共地佔組合物之約〇 〇5%至約 ,例如約0.1%至約7%,或約0.2%至約5重量%。膠體 一乳化石夕爲一極有效助流劑。 其他賦形劑,諸如緩衝劑、安定劑、抗氡化劑抗微生 物劑、著色劑、調味劑及甜咮劑,爲醫藥技術中已知且可 於本發明之組合物中使用。錠劑可未經塗覆或可包含諸如 經非功能性膜或改質釋放或腸包衣塗覆之核。膠囊可具有 諸如含明膠(以硬質明膠膠囊或軟質彈性明膠膠囊)、澱 粉、鹿角菜膠及/或HPMC,及視需要之一種或多種增塑劑 之硬或軟殼。 本發明之可經口遞送之固態組合物不受任意常製備的方 147960.doc -34 - 201041882 法限制。可使用藥物之任意適宜方法,包含直接壓製下或 不直接壓製之乾摻合,及濕或乾法製粒。 如組合物製備成液體(包含囊封液體)形式,可將 αΡΙ(αβτ·263雙_HC1)例如溶於適宜載劑中,通常為包含用 .於API之脂溶劑的載劑。單位劑量越高,越需選擇其溶液 中可含較尚濃度藥物之載劑。通常,載劑中Αρι之游離鹼 等效物農度爲至少約1〇 mg/ml,例如約1〇至約5〇〇 〇 mg/m1,但於特定情況中可接受或達成更低及更高濃度。 具體而言,於多個實施例中’藥物濃度為至少約1〇 mg/m卜例如,約10至約4〇〇 mg/mi,或至少約2〇 mg/mi, 例如,約20至約200 mg/m卜例如約2〇、約25、約3〇、約 4〇、約 50、約 75、約100、約 125、約 15〇或約 2〇〇mg/mi。 載劑實質上可係非水性的,即不含水,或具有少到實際 上對組合物性能或性質基本上無害的水量。通常載劑含 〇至低於約5重量%之水。應瞭解文中有效的特定成分可結 〇 合其分子或超分子結構上或内之少量水;此等結合水(如 存在)實質上不影響如文中定義之載劑的「實質上非水性 的」特徵。 於一些實施例中,載劑包含一或多種甘油酯物質。適宜 的甘油酯材料包含但不限於中至長鏈的單、雙及三甘油 S旨。術語「申鏈」文中指分別具有不少於約6個及少於約 12個碳原子之烴基鏈,包含諸如&至Cig鏈。因此包含辛 醯基及癸醯基鏈之甘油酯物質(例如辛酸/癸酸單_、雙-及/ 或二甘油酯)為文中「中鏈」甘油酯物質之實例。文中術 147960.doc -35 - 201041882 語「長鏈」指分別具有至少約12,例如約12至約18之碳原 子的烴基鏈,包含月桂基、肉豆蔻基、鯨蠟基、硬脂醯 基、油醯基、亞油醯基及亞油基鏈。甘油酯物質中之中至 長鏈烴基可飽和、單或多不飽和。 於一實施例中,载劑包含一中鏈及/或一長鏈三酸甘油 酯物質。中鏈三酸甘油酯物質之適宜實例爲辛酸/癸酸三 酸甘油酯’諸如,Abitec公司的Captex 355 ΕΡΤΜ及實質上 相當產品。長鏈三酸甘油酯之適宜實例包含任意醫藥上可 接文的植物油’諸如油菜籽、椰子、玉米、棉籽、亞麻 子、撖欖、棕搁、花生、紅花、芝麻、大豆及向日葵油, 及此等油之混合物。亦可使用動物(特定言之海洋動物)源 之油,包含諸如魚油。 發現特別有效之載劑系統包含兩主要組分:一磷脂及一 用於填脂之醫藥上可接受的助溶劑。應瞭解對一(或該)磷 脂、助溶劑或文中其他調配物成分之單數形式的參照包含 複數;因此,文中明確涵蓋一種以上的磷脂,或一種以上 的助溶劑之組合(諸如混合物)。雖然視需要存在於載劑中 之載劑成分(諸如界面活性劑或諸如乙醇之醇)於一些情况 中可增强藥物溶解,但助溶劑,或助溶劑及磷脂之組合亦 使藥物增溶。 可使用任意醫藥上可接受的磷脂或磷脂混合物。通常而 吕’此等碟脂爲經水解鱗酸、脂肪酸、酵及含氮驗產生的 填酸酯。醫藥上可接受的磷脂可包含但不限於磷酯醯膽 驗、磷脂醯絲胺酸及磷脂醯乙醇胺。於一實施例中’組合 147960.doc -36- 201041882 物包含例如衍生自天然㈣脂之碟醋酿膽驗。可使用任何 來源的㈣脂,包含動物來源,諸如蛋黃但植物來源通 常較佳。大豆爲極富含印磷脂源,其可提供用於本發明之 磷酯醯膽鹼。 具體而言,錢之適宜量為载劑之約15%至約75%,例 如約30%至約60重量%,即使於特定情況中可使用更多及 更少量。 未特別限制作爲助溶㈣分之成分且在某㈣度上將取 决於所需的藥物及鱗脂濃度。於一實施例中,助溶劑包含 -或多種二醇、一或多種乙交醋及/或一或多種甘油醋物 質。 適宜的二醇包含丙二酵及分子量為約2〇〇至約1〇〇〇 g/mol之聚乙二醇(PEG),例如平均分子量為約4〇〇 g/m〇i之 PEG-400。此等二醇可提供藥物較高溶解性;但當藥物溶 於含有此等二醇之載劑時之氧化降解之潛在性增加,例如 ❹ 原因在於一醇產生超氧化物、過氧化物及/或游離羥基之 趨勢。載劑之二醇含量越高,化學上不安定的藥物之降解 趨勢可能就越強。因此,於一實施例中,一或多種二醇之 總二醇量係載劑之至少約1%但小於約5〇%,例如小於約 30 /〇,小於約20%,小於約丨5。/。或小於約丨〇重量%。於另— 實施例中,載劑實質上不含二醇。 乙交酯爲經一或多種有機酸(諸如中至長鏈脂肪酸)酯化 的二醇類(諸如丙二醇或PEG)e適宜實例包含丙二醇單辛 酸醋、丙二醇單月桂酸醋及丙二醇二月桂酸醋産品,諸如 147960.doc -37- 201041882 分別爲 Abitec Corp 之 Capmul PG-8TM、Capmul PG-12TM 及 Capmul PG-2L™及實質上相當之產品。 可與磷脂一起使用之適宜甘油酯物質包含但不限於上述 彼等。當一或多種甘油酯物質係以助溶劑之主要組分存在 時,甘油酯之總適宜量爲使磷脂及載劑之其他組分溶解之 有效量、保持藥物及抗氧化劑於溶解態之有效量。例如, 諸如中鏈及/或長鏈三酸甘油酯之甘油酯物質之總甘油酯 量可爲載劑之約5%至約70%,諸如約1 5%至約60%或約 25%至約50重量%。 如需要’可包含除二醇或甘油酯外的其他助溶劑。於特 定情況中’例如N-經取代的醯胺溶劑(諸如二曱基甲醯胺 (DMF)及N,N-二甲基乙醯胺(DMA))之此等製劑利於提高藥 物於載劑中之溶解限值,進而增加藥物負載。但是,文中 有效的載劑通常提供文中所關心的小分子藥物之足夠溶解 性,且無需另添加此等製劑。 即使於爲溶解磷脂存在足量二醇、乙交酯或甘油酯物質
障的趨勢。通常而言 適於例如藥物-栽劑系統係以明膠膠囊 原因在於高乙醇濃度導致膠囊之機械故 口 3 ’乙醇之適宜量為載劑之〇%至約 147960.doc -38- 201041882 25°/。,例如約ι%至約2〇%或約3%至約15重量%。 視情况地,載劑進一步包含一醫藥上可接受的非磷脂界 面活性劑。熟悉此技術者可選擇適用於本發明之組合物的 界面活性劑。舉例而言,可包含量為載劑之〇%至約5% ’ 例如0%至約2%或0%至約2%或〇%至約丨重量%之界面活性 劑(諸如聚山梨醇酯)。 便利地’可購得包含適用於本發明之組合物的磷脂十助 0 溶劑組合之經預摻合的産品。經預摻合的磷脂+助溶劑產 品利於增進製備本發明組合物之簡易性。 經預摻合的磷脂+助溶劑產品之具體實例為購自 Phospholipid GmbH,德國之Phosal 50 PG™,其包含至少 50重量%磷酯醯膽鹼、至多6重量。/❶溶血磷脂醯膽驗、約35 重I:%丙一醇、約3重量%來自向日葵油之單-及二酸甘油 酯、約2重量%大豆脂肪酸、約2重量%乙醇、及約〇.2重量 %抗壞血酸棕櫚酸酯。 ❹ 另一具體實例為亦購自Phospholipid GmbH之Phosal 53 MCT™,其包含至少53重量%磷酯醯膽鹼、至多6重量%溶 血麟脂醯膽驗、約29重量%中鏈三酸甘油酯、3-6重量 %(通常約5%)乙醇、約3重量%來自向曰葵油之單-及二酸 甘油酯、約2重量%油酸、及約〇.2重量%抗壞血酸棕櫚酸 酯(參照組成)。具有上述或實質上相當組成之產品,無論 係以Phosal 53 MCTtm商標出售或其他,於文中種屬上係 指「磷酯醯膽鹼+中鏈三酸甘油酯53/29」。具有「實質上 相當組成」之産品於本發明中意指其組成極類似於成分表 147960.doc 39· 201041882 列中的參考組成’且成分相對量對就文中産物之利用而言 的性質未顯示實際差異之組合物。 又另一具體實例為購自Lipoid GmbH之Lipoid S75™,其 增溶系統中包含至少70重量%磷酯醯膽鹼。此可例如以 30/70重量比混合物進一步與中鏈三酸甘油酯摻合,以産 生含至少20重量%磷酯醯膽鹼、2_4重量%磷脂醯乙醇胺、 至多1.5重量❶/〇溶企磷脂醯膽鹼、及67_73〇/〇中鏈三酸甘油酯 之產物(「Lipoid S75TM MCT」)。 又另具體實例為亦購自Phospholipid GmbH之Phosal 5 0 SA+tm ’其包含紅花油及其它成分之增溶系統中包含至 少50重量%磷酯醯膽鹼及至多6%溶血磷脂醯膽鹼。 此等經預摻合之産品中每—者之磷酯醯膽鹼組分係源自 大I卵磷脂。組成實質上相當之產品可購自其他供應者。 於些實施例中’諸如Phosal 50 PGTM、Phosal 53 MCTtm、Lip01d S75tm MCT^ph〇sal 5〇 SA+TM之經預摻合 的產物實質上構成整個載劑系統。於其他實施例中,存在 其他成分,諸如乙醇(除可存在於經預摻合的產品中之任 意乙醇)、非磷脂表面活性劑(諸如聚山梨醇酯8〇)、聚乙二 醇及/或其他成分。通常僅含少量此等其他成分(如存在)。 具體而言,磷酯醯膽鹼+中鏈三酸甘油酯53/29可以載劑之 .•勺50 /〇至1 〇〇重量%,諸如約至1 〇〇重量%之量含於載劑 中。 ABT-263及其雙_HC1鹽於氧化環境中易降解;因此組合 物中期望含有抗氧化劑。醫藥組合物中所用的抗氧化劑爲 147960.doc -40· 201041882 抑制氧化類物質(諸如三 物及游離羥產n & 一〜、、超氧化物、過氧化 各丞)產生最常用的製太 氧化類物質之製劑。常…"、如此等產生的 基化經基笨甲::類抗氧化劑之實例包含丁 I本甲鰱(BHA)、丁基化羥基 棕櫚酸酯、生育酚、扭@ $ t ( HT)、視黃基 詩 彳。酸㈣、抗壞血岐抗壞血酸棕櫊 =效可❹此等抗氧化劑,另,較重之硫族抗氧化劑尤
硫族爲週期表16族(先前稱爲VIA族)之元素,包含氧、 硫、硒及碲。「較重之硫族」文中意指原子量較氧重之硫 族’具體包含硫及.「較重硫族抗氧化劑」&「嶋」 爲一種含有一個或多個可氧化之硫或硒原子,特定言之硫 原子之具有抗氧化性的化合物。未受理論限制,認爲hca 主要作爲競爭基質,即作爲「犧牲」抗氧化劑,其優先受 到氧化性物質攻擊進而保護藥物免遭過度降解。 於一些實施例中,HCA包含一或多種式„之抗氧化劑化 合物: Y2
II V3 其中 η為0,1或2 ; Υ1為S或Se ; Y2為NHR1、OH或Η,其中R1為烷基或烧幾基; Υ3為COOR2或CH2OH,其中R2為Η或烷基;及 R3為Η或烷基; 147960.doc -41- 201041882 其中烷基獨自地視需要經一或多個獨自地選自由以下基團 組成之群的取代基取代:羧基、烷羰基、烷氧幾基、胺基 及烷羰基胺基;或其醫藥上可接受的鹽;或Y1為S及R3為 Η之其-S-S-二聚體或此二聚體之醫藥上可接受的鹽。 於另一些實施例中’ HCA為式III之抗氧化劑化合物: R4〆丫、R5 ΙΠ 其中 Υ為S、Se或S-S ;及 R4及R5獨自地選自Η、烷基及(CH2)nR6其中11為〇_1〇及&6 為芳羰基' 烷羰基、烷氧羰基、羧基或經chr7rS_取 代之烧基’其中R7及R8獨自地為CO〆、CH2〇H '氣 或NHR ,其中R9為Η、烧基、經取代之烧基或芳燒 基及R1Q為氫、烷基、烷羰基或烷氧羰基。 「烷基」取代基或形成符合式Η或式⑴取代基一部分之 「烷基」或「烷氧基」係具有丨至約18個碳原子者且可由 直鏈或支鏈組成。 符合式III之形成取代基一部分之「芳基」為未經取代或 經一或多個羥基、烷氧基或烷基取代之苯基。 於一些實施例中,式„中之R、Ci4院基(例如甲基或乙 基)或(Ci_4烧基)幾基(例如乙酿基)。 於一些實施例中,式Π中之112為^1或(:1-18烷基,例如▼ 基、乙基、丙基(例如,正丙基或異丙基)、丁基(例如,正 丁基、異丁基或第三丁基)、辛基(例如,正辛基或2_乙基 己基)、十二烷基(例如,月桂基)、十三烷基、十四烷基、 147960.doc •42- 201041882 十六烧基或十八烧基(例如,硬脂基)。 R —般為Η或匚〗·4炫基(例如,甲基或乙基)。 HCA可例如爲天然或合成胺基酸或其衍生物(諸如烷基 酯或Ν-醯基衍生物)、或此胺基酸或衍生物之鹽。胺基酸 或其衍生物係衍生自天然來源時,其通常為L_組態;但是 應瞭解D-異構體及D,L-異構體混合物必要時可經取代。 文中有效的HCA之非限制性實例包含β烷基毓基酮、半 胱胺酸、胱胺酸、高半胱胺酸、甲硫胺酸、硫代二乙酸、 硫代二丙酸、硫甘油、晒半胱胺酸、砸甲硫胺酸及其鹽、 醋、醯胺及硫醚;及其等組合。特定言之,一或多種HCA 可選自Ν-乙酿半胱胺酸、Ν-乙酿半胱胺酸丁基酯、Ν_乙醯 半胱胺酸十二院基酯、Ν-乙酿半胱胺酸乙酯、Ν-乙醯半胱 胺酸甲酯、Ν-乙醯半胱胺酸辛基酯、N—乙醯半胱胺酸丙 酯、Ν-乙醢半胱胺酸硬脂醯酯、Ν-乙醢半胱胺酸十四烧基 酯、Ν-乙醯半胱胺酸十三烧基酯、Ν-乙酿甲硫胺酸、Ν-乙 醯曱硫胺酸丁基酯、Ν-乙醯曱硫胺酸十二烧基酯、Ν-乙酿 甲硫胺酸乙基酯、Ν-乙醯甲硫胺酸曱基酯、ν-乙醯甲硫胺 酸辛基酯、Ν-乙醯曱硫胺酸丙基酯、Ν-乙醯曱硫胺酸硬脂 醯酯、Ν-乙醯甲硫胺酸十四烷基酯、Ν-乙醯甲硫胺酸十三 烷基酯、Ν-乙醯基硒半胱胺酸、Ν-乙醯基硒半胱胺酸丁基 酯、Ν-乙醯基硒半胱胺酸十二烷基酯、Ν-乙醯基硒半胱胺 酸乙酯、Ν-乙醯基硒半胱胺酸甲酯、Ν-乙醯基硒半胱胺酸 辛基酯、Ν-乙醯基硒半胱胺酸丙酯、Ν-乙醯基硒半胱胺酸 硬脂醯酯、Ν-乙醯基硒半胱胺酸十四烷基酯、Ν-乙醯基硒 147960.doc • 43- 201041882 半胱胺酸十二烷基酯、N-乙醯基硒甲硫胺酸、N—乙醯基硒 甲硫胺酸丁基酯、N-乙醯基硒曱硫胺酸十二烷基酯、n_6 醯基硒甲硫胺酸乙酯、N-乙醯基硒甲硫胺酸甲酯、N_乙醯 基硒甲硫胺酸辛基酯、N-乙醯基硒曱硫胺酸丙酯、N_乙醯 基硒甲硫胺酸硬脂醯酯、N-乙醯基硒曱硫胺酸十四烷基 醋、N-乙醯基砸甲硫胺酸十三烷基酯、半胱胺酸、半胱胺 酸丁基醋、半胱胺酸十二烧基酯、半胱胺酸乙酯、半胱胺 酸曱酯、半胱胺酸辛基酯、半胱胺酸丙酯、半胱胺酸硬脂 醯酯、半胱胺酸十四烷基酯、半胱胺酸十三烷基酯、胱胺 酸、胱胺酸二丁酯、胱胺酸二(十二烷基)酯、胱胺酸二乙 酯、胱胺酸二曱酯、胱胺酸二辛酯、胱胺酸二丙酯、胱胺 酸二硬脂醯酯、胱胺酸二(十四烧基)酯、胱胺酸二(十三烧 基)酯、Ν,Ν-二乙醯基胱胺酸、Ν,Ν-二乙醯基胱胺酸二丁 酯、Ν,Ν-二乙醯基胱胺酸二乙酯、Ν,Ν-二乙醯基胱胺酸二(十 二烷基)酯、Ν,Ν-二乙醯基胱胺酸二曱酯、Ν,Ν-二乙醯基胱胺 酸二辛酯、Ν,Ν-二乙醯基胱胺酸二丙酯、Ν,Ν-二乙醯基胱胺 酸二硬脂醯酯、ΗΝ-二乙醯基胱胺酸二(十四烷基)酯、Ν,Ν-二乙醯基胱胺酸二(十三烷基)酯、硫代二乙二醇二丁基 酯、硫代二丙酸二丁基酯、硫代二乙二醇二(十二烷基) 酯、硫代二丙酸二(十二烷基)醋、硫代二乙二醇二乙酯、 硫代二丙酸二乙醋、硫代二乙·一醉一甲硫代—丙酸·一 甲酯、硫代二乙二醇二辛酯、硫代二丙酸二辛酿、硫代二 乙二醇二丙酯、硫代二丙酸二丙酯、硫代二乙二醇二硬脂 醯醋、硫代二丙酸二硬脂醯酯、硫代二已二醇二(十四烧 147960.doc -44- 201041882 基)酯、硫代二丙酸二(十四烷基)酯、高半胱胺酸、高半胱 胺酸丁基酯、高半胱胺酸十二烷基酯、高半胱胺酸乙酯、 高半胱胺酸甲酯、高半胱胺酸辛基酯、高半胱胺酸丙酯、 间半胱胺酸硬脂醯酯、高半胱胺酸十四烷基酯、高半胱胺 酸十二烷基酯、甲硫胺酸、甲硫胺酸丁基酯、甲硫胺酸十 一烷基酯、甲硫胺酸乙酯、曱硫胺酸甲酯、甲硫胺酸辛基 酯、甲硫胺酸丙酯、甲硫胺酸硬脂醯酯、甲硫胺酸十四烷 〇 基酯、甲硫胺酸十三烷基酯、s-甲基半胱胺酸、s-甲基半 胱胺酸丁基酯、S-甲基半胱胺酸十二烷基酯、s—曱基半胱 胺酸乙酯、S-甲基半胱胺酸甲酯、s_甲基半胱胺酸辛基 酯、S-甲基半胱胺酸丙酯、s_甲基半胱胺酸硬脂醯酯、s_ 甲基半胱胺酸十四烷基酯、S_甲基半胱胺酸十三烷基酯、 硒半胱胺酸、硒半胱胺酸丁基酯、硒半胱胺酸十二烷基 酯、硒半胱胺酸乙酯、硒半胱胺酸曱酯、硒半胱胺酸辛基 醋、砸半胱胺酸丙酯、硒半胱胺酸硬脂醯酯、硒半胱胺酸 〇 十四烧基醋、砸半胱胺酸十三烷基酯、硒甲硫胺酸、硒甲 输胺酸丁基酯、硒甲硫胺酸十二烷基酯、硒甲硫胺酸乙 醋、砸甲硫胺酸甲酯、硒甲硫胺酸辛基酯、硒甲硫胺酸丙 醋、石西甲硫胺酸硬脂醯酯、硒甲硫胺酸十四烷基酯、硒曱 硫胺酸十三烷基酯、硫代二乙酸、硫代二丙酸、硫甘油、 異構體及其異構體之混合物、及其鹽。 HCA化合物之鹽可爲酸加成鹽,諸如醋酸鹽、己二酸 鹽、藻酸鹽、碳酸氬鹽、檸檬酸鹽、天冬胺酸鹽、苯曱酸 鹽、苯磺酸鹽、硫酸氫鹽、丁酸鹽、樟腦酸鹽、樟腦磺酸 147960.doc -45- 201041882 鹽、雙葡萄醣酸鹽、甲酸鹽、富馬酸鹽、甘油磷酸鹽、榖 胺酸鹽、半硫酸鹽、庚酸鹽、己酸鹽、鹽酸鹽、氫溴酸 鹽、氫碘酸鹽、乳糖酸鹽、乳酸鹽、馬來酸鹽、均三甲苯 績SiL鹽、甲㉖酸鹽、萘確酸鹽、烟驗酸鹽、草酸鹽、雙經 萘酸鹽、果膠酸鹽、過硫酸鹽、磷酸鹽、苦味酸鹽、丙酸 ^ 丁 一酸鹽、酒石酸鹽、硫氰酸鹽、三氣醋酸鹽、三氟 醋酸鹽、對曱苯磺酸鹽及十—烷酸鹽。於一特定實施例 中’上述任意化合物之鹽酸鹽可以抗氧化劑有效量存在於 組合物中。 又理-限制,普遍認爲較重硫族抗氧化劑(諸如以」 列舉者)錯由使其自身更易氧化而保護活性化合物,及g 此較藥物化合物優純化。通常而言,對於以提供藥物七 合物可接受的保護程度之操作方式,抗氧化劑需以基本J 存在,例如與藥物化合物之莫耳比爲至少約i : 1〇。於一 些實施例中’抗氧化劑與藥物化合物之莫耳比爲約1: Γ 至約2:卜例如約1:5至約15:1。當莫耳比為約⑺, 即約8:10至約10:8時’有時可獲得最佳結果。 上述HCAy由不同類的含硫抗氧化劑替代,即亞硫酸 瓜、亞硫酸氫鹽、偏亞硫酸氫醆 , 虱|及^代硫酸鹽之無機抗氧 化Μ。為使事件複雜化,此黧俨 、 此4抗氧化劑較難溶於脂類且需 入以脂類爲主的載劑或藥物_載劑系統之水溶液卜水 之存在利於亞砜於ΑΒΤ-263溶$ ψ ^ , 成’應將不良效果降 至最低。爲限制所添加的水詈, ^ ^ , 斤添加的較難溶於脂類的 几月之;度-般遠低於提供與斯如莫耳等效的抗 147960.doc • 46 - 201041882 氧化劑。 當使用較難溶於脂類的抗氧化劑(諸如亞硫酸鹽、亞硫 酸氫鹽、偏亞硫酸氫鹽或硫代硫酸鹽抗氧化劑)時,藥物_ 載劑系統之水量不超過約i重量%’例如約〇 2%至約〇 8重 量=可引人此少量水之該抗氧化劑之量通常不超過約〇 2 重里/。’且例如量為藥物_載劑系統之約〇.㈣至約ο ]重量 %,或約0.05%至約0.15重量0/〇。
為將加入調配物之水量降至最低,最佳提供以相對較濃 的水性儲備溶液形式之抗氧化劑,例如具有至少約1〇重量 %之抗氧㈣。但,已發現使用過濃館備溶液(例如約鳩 或更高)時,調配物中可産生不需要的固體沉殿。健備溶 液中抗氧化劑之適宜濃度一般為約1〇%至約18重量%,具 體言之約15重量%。 ' 偏亞硫 劑,特 根據本發明之實施例,亞硫酸鹽、亞硫酸氫鹽、 ,氫鹽及硫代硫酸鹽之納鹽及鉀鹽爲有效的抗氧化 定言之偏亞硫酸氫鈉及卸。 為進-步將亞碾之形成降至最低,視需要添加螯合劑 (諸如EDTA或其鹽(例如,EDTA二納或ε〇τα二納仙,其 罝例如為藥物-載劑系、统之約〇.〇〇2%至約〇〇2重量%。 肋TA可以與抗氧化劑相同的方式以水性健備溶液添加。 4化劑及EDTA(如需要)可以同一赌備溶液之組分添 加。螯合劑螯合可促進氧化降解之金屬離子。 可藉由選擇具有低過氧化值之調配物成分而進-步將亞 石風之形成降至最低。過氧化值爲醫藥賦形劑之明確性質且 147960.doc -47- 201041882 單位,常表示(如本文)爲毫當量過氧化物/千克賦形劑 (職^)。-些職形劑本身具有低過氧化值,而另—些, 諸如油稀基及/或聚環氧乙燒鏈的不飽和脂肪酸 ,可為過氧化物源。就聚山梨醇醋8〇而言,例 如’最佳選擇過氧化值不大於約5’例如不大於約2之聚山 梨醇醋8〇源。適宜源包含皆購自㈤a之Crillet 4_及
Super-Refined Tween 80TM。 ^受理論限制,認爲ABT摘之治療效能至少部分係因 爲八以抑制蛋白之抗调亡的方式(例如藉由佔據蛋 BH3鍵結溝)結合至_家族蛋白(諸如B Bcl-w)之能力。 月2之又另一實施例而言,其提供-種治療特徵為 二法,V蛋白之〉周亡功能奮亂及/或過度表達之疾病 、,/、包含對患有此疾病之個體投與治療有效量之 娜263雙侧或含有繼加雙·及-種或多種醫華 上可接受的賦形劑之醫藥組合物。 患者可爲人或非人(例如,農場、動物園、役用或伴侣 動物或作爲模型之實驗室動物),但於一重要實施例 中’個體為需要藥物例如以治療特徵為抗〉周亡Bcl-2族蛋
白之源亡功能紊亂及/或過度表達之疾病之人類患者。、人 類個體可為男性$ + M 乃『生次女性且年齡不限。患者一般爲成人但 本毛明之方法可用於治療兒科患者之兒童期癌症’例如白 血病’諸如急性淋巴細胞性白血病。 口物奴係以提供治療有效日劑量之藥物之量投與。 147960.doc •48· 201041882 術語「曰劑量」本文意指每日所投與的藥物量,與投盥頻 率無關。例如,如果個體接受150 mg之單位劑量且每天兩 次,則曰劑量為3〇〇 mg。術語「曰劑量」之使用不應理解 為意指需每曰一次投與特定劑量量。但是,於一特定實施 例中,投藥頻率為每曰-次叫貝曰劑量及單位劑量 於此實施例中為同一者。 ❹ Ο 産生治療有效劑量取决於特定調配物之生物利用率、個 體(包含該個體之種類及體重)、待治療之疾病(例如,特定 種類的癌症)、疾病的階段及/或嚴重性、每個個體對化合 物之耐受性、化合物係以單葯治療或與一或多種其它藥: (例如,治療癌症之其他化療劑)組合投與' 及其它因素。 因此’日劑量可寬範變化,例如約1〇至約吨。更多 或更少日劑量於特^情況下係適宜的。應瞭解文中所引用 的「治療有效」劑量如僅投與此單一劑量則不需藥物治療 上有效m療效能取决於根據包含適宜頻率及投與間 隔之療程所重複投與的組合物。最佳爲,#所選的日劑量 就治療癌症而言;1以提供益處時,不應引起有害的副作用 至不可接受或無法忍、受的程度。適宜的治療有效量可由擅 長醫師基於文中揭示内容及文中所引用的技術無需過度試 驗且考慮如上述所述的因素而選擇。例如,醫師可以相對 較低的日劑量對癌症患者開始u治療且在若干日或週 内滴定劑量向上,以降低有害的副作用之風險。 具體而言,ABT-263之適宜劑量一般為約25至約1;〇〇〇 mg/天,更常見為約50至約5〇〇 mg/天或約2〇〇至約4〇〇 mg/ 147960.doc -49- 201041882 天例如約50、約loo、約15()、約_、約25〇、約_、 約 '、'勺400、約450或約50〇 mg/天,投與之平均投藥間 隔為約3小時至約7天,例如約8小日寺至約3天,或約^小時 至約2天。於大多數情況下,_天―次㈣)之投與療法為 適宜的。 平均投藥間隔」文中定義爲時間跨度(例如一天或— 週)除以此時間跨度内投與單位劑量之次數。例如,藥物 -天投與三次時,約早上8點,近中午及約下午6點則平 均投藥間隔為8小時(24小時的時間跨度除以3)。如藥物係 調配成不連續劑型(諸如錠劑或膠囊),將認爲每次投與的 複數個(例如,2至約10個)劑型為單位劑量以定義平均投藥 間隔。 μ 於一些實施例中,可選擇日劑量量及投藥間隔以保持 ΑΒΤ-263之血漿濃度於約〇.5至约1()叫㈤之間。因此,根 據此等實施例,於ABT_263治療療程期間,穩態血漿濃度 峰(Cmax)通常應不超過約10 gg/m卜且穩態血漿濃度谷值 (Cmin)通常應不低於約05 μ§/ϊη卜另發現最佳選擇上述範 圍内之日劑量量且穩態下有效提供不大於約5 ,例如不大 於約3之Cmax/Cmin之平均投藥間隔。應瞭解更長的投藥間 隔將産生更大的Cmax/Cmin比。具體而言,穩態下,本發明 指定約3至約8 pg/mliABT_263Cmax及約i至約5吨/w之 Cmin。可於人類PK研究中確定(^及^之穩態值,該研 究例如根據標準協定進行,包含但不限於諸如美國食品藥 品管理局(FDA)之管理機構所接受的標準協定。 147960.doc -50- 201041882 因認爲本發明之組合物僅展現較小食物影響,故根據本 發明實施例之投與可隨餐或不隨餐,即非禁食或禁食狀 態。通常’最佳將本發明之組合物投與至非禁食患者》 本發明之組合物適於單藥療法或例如與其他化療法或電 離輻射之組合療法。本發明之特別益處在於其可每日一次 進行經口投與,療法便於以每日一次之療法由其他經口投 與之藥物治療的患者。經口投與易由患者自身或患者住所 的看護者完成;其亦爲醫院或居家型照料機構之患者的便 利投與途徑。 組合療法具體包含投與包含ABT-263雙-HC1與硼替佐米 (bortezomid)、卡鉑、順鉑、環填醯胺、達卡巴嗪 (dacarbazine)、地塞米松(dexamethasone)、多西他赛 (docetaxel)、多柔比星(doxorubicin)、依託泊皆(etoposide) 、氣達拉濱(fludarabine)、經基多柔比星(hydroxydoxorubicin) 、伊立替康(irinotecan)、紫杉醇(paclitaxel)、雷帕黴素 (rapamycin)、利妥昔單抗(rituximab)、長春新驗(vincristine) 等中之一者或多者,例如與多藥治療,諸如CHOP(環磷醯 胺+羥基多柔比星+長春新鹼+强的松)、RCVP(利妥昔單抗 +環磷醯胺+長春新鹼+强的松)、R-CHOP(利妥昔單抗 +CHOP)或DA-EPOCH-R(劑量經調整之依託泊苷、强的 松、長春新鹼、環磷醯胺、多柔比星及利妥昔單抗)之本 發明的組合物。 於組合療法中,含ABT-263雙-HC1的本發明之組合物可 與一或多種治療劑投與,此等治療劑包含但不限於血管新 147960.doc -51 · 201041882 生抑制劑、抗增殖劑、其他调亡促進劑(例如’ Bcl_xL、 Bcl-w及ΒΠ-1抑制劑)、死亡受體途徑之活化劑、BiTE(雙 特異性T-細胞反應劑)抗體、雙可變域結合蛋白(DVD)、凋 亡蛋白抑制劑(IAP)、微RNAs、絲裂原活化細胞外信號調 節激酶抑制劑、多價結合蛋白、聚-ADP(腺普二麟酸)_核 糖聚合酶(PARP)抑制劑、小抑制性核糖核酸(siRNA)、激 酶抑制劑、受體酪胺酸激酶抑制劑、aurora激酶抑制劑、 polo樣激酶抑制劑、bcr-abl激酶抑制劑、生長因子抑制 劑、COX-2抑制劑、非甾體類消炎藥物(NSAID)、抗有絲 分裂劑、烧化劑、抗代謝物、插入式抗生素、含銘之化療 劑、生長因子抑制劑、電離輻射、細胞週期抑制劑、酶、 拓撲異構酶抑制劑、生物反應調節劑、免疫製劑、抗體、 荷爾蒙療法、類視黃醇、deltoids、植物驗、蛋白酶體抑 制劑、HSP-90抑制劑、組蛋白脫乙醯基酶(HDAC)抑制 劑、嗓吟類似物、β密咬類似物、MEK抑制劑、CDK抑制 劑、ErbB2受體抑制劑、mTOR抑制劑及其他抗癌劑。 血管新生抑制劑包含但不限於EGFR抑制劑、PDGFR^P 制劑、VEGFR抑制劑、TIE2抑制劑、IGF1R抑制劑、基質 金屬蛋白酶2(MMP-2)抑制劑、基質金屬蛋白酶9(MMP-9) 抑制劑及凝血因子類似物° EGFR抑制劑之實例包含但不限於吉非替尼(gefitinib)、 埃羅替尼(erlotinib)、西妥昔單抗(cetuximab)、EMD-7200、ABX-EGF、HR3、IgA抗體、TP-38(IVAX)、EGFR 融合蛋白、EGF-疫苗、抗-EGFR免疫脂質體及拉帕替尼 147960.doc •52· 201041882 (lapatinib) 〇 PDGFR抑制劑之實例包含但不限於CP-673451及CP-868596 ° VEGFR抑制劑之實例包含但不限於貝伐單抗 (bevacizumab)、蘇尼替尼(sunitinib)、索拉非尼(sorafenib) 、CP-547632、阿西替尼(axitinib)、凡德他尼(vandetanib) 、AEE788、AZD-2171、VEGF拼、凡他拉尼(vatalanib)、 0瓜加他尼(pegaptanib)、IM862、帕嗤帕尼(pazopanib)、 ABT-869及安吉甾姆(angiozyme)。
Bcl-2族蛋白抑制劑除ABT-263或文中式I化合物外,亦 包含但不限於AT -101((-)棉子紛)、Genasense™ Bcl-2-乾向 反義寡核苷酸(G3139或奥利默森(oblimersen))、IPI-194、 IPI-565、ABT-737、GX-070(obatoclax)等。 死亡受體途徑之活化劑包含但不限於TRAIL、靶向死亡 受體(例如DR4及DR5)之抗體或其他製劑,諸如埃波單抗 (apomab)、考那木單抗(conatumumab)、ETR2-ST01、 GDC0145(來沙木單抗(16乂&比11111111&1)))、11〇8-1029、1^丫-135、PRO-1762及曲妥珠單抗(trastuzumab)。 凝血因子類似物之實例包含但不限於TSP-1、ABT-510、ABT-567及 ABT-898。 aurora激酶抑制劑之實例包含但不限於VX-680、AZD-1152及 MLN-8054。 polo樣激酶抑制劑之實例包含但不限於BI-2536。 bcr-abl激酶抑制劑之實例包含但不限於伊馬替尼 147960.doc -53- 201041882 (imatinib)及達沙替尼(dasatinib)。 含鉑製劑之實例包含但不限於順鉑、卡鉑、依鉑、樂 鉑、奈達鉑、奥沙利鉑及沙鉑。 mTOR抑制劑之實例包含但不限於CCI-779、雷帕黴素 (rapamycin)、西羅莫司(temsirolimus)、依維莫司(everolimus) 、RAD001 及 AP-23573。 HSP-90抑制劑之實例包含但不限於格爾德黴素 (geldanamycin)、根赤般菌素(radicicol)、17-AAG、KOS-953、17-DMAG、CNF-101、CNF-1010、17-AAG-nab、 NCS-683664、依芬古單抗(efungumab)、CNF-2024、 PU3、PU24FCM、VER-49009、IPI-504、SNX-2112及 STA-9090 ° HDAC抑制劑之實例包含但不限於辛二醯基苯胺異羥肟 酸(SAHA)、MS-275、丙戊酸 ' TSA、LAQ-824、曲普辛 (trapoxin)及縮盼肽。 MEK抑制劑之實例包含但不限於PD-325901、ARRY-142886、ARRY-438162及PD-98059。 CDK抑制劑之實例包含但不限於flavopyridol、MCS-5A、CVT-2584、塞利西裏(861沁1(^1))2〖-304709、?11八-690509、BMI-1040、GPC-286199、BMS-387032、PD-332991 及 AZD-5438。 COX-2抑制劑之實例包含但不限於塞來考昔(celecoxib)、 帕瑞考昔(parecoxib)、德拉昔布(deracoxib)、ABT-963、 依託西蔔(etoricoxib)、羅美昔布(lumiracoxib)、BMS- 147960.doc •54- 201041882 347070、RS 57067、NS-398、伐地考昔(valdecoxib)、羅 非考昔(rofecoxib)、SD-8381、4-甲基-2-(3,4-二甲苯基)-1-(4-胺磺醯基苯基)-1Η-吡咯、T-614、JTE-522、S-2474 ' SVT-2016、CT-3及 SC-58125。 NSAID之實例包含但不限於雙水楊酸酯、雙氟尼酸、布 洛芬(ibuprofen)、酮基布洛芬(ketoprofen)、萘丁美酮 (nabumetone)、°比羅昔康(piroxicam)、萘普生(naproxen)、 雙氣芬酸(diclofenac)、°引11朵美辛(indomethacin)、舒林酸 (Sulindac)、托麥汀(tolmetin)、依托度酸(etodolac)、酮0各 酸(ketorolac)及奥沙普嗪(oxaprozin)。
ErbB2受體抑制劑之實例包含但不限於CP-724714、卡納 替尼(canertinib)、曲妥珠單抗(trastuzumab)、帕妥珠單抗 (pertuzumab)、TAK-165、ionafamib、GW-282974 ' ΕΚΒ-569、PI-166、dHER2、APC-8024、抗-HER/2neu雙特異性 抗體B7.her2IgG3及HER2三官能性雙特異性抗體mAB AR-209及 mAB 2B-1。 烷化劑之實例包含但不限於氮芥氮氧化物、環磷醯胺、 異環磷醯胺、曲磷胺、苯丁酸氮芥、美法侖、白消安、二 溴甘露醇、卡波醌(carboquone)、嘆替^瓜(thiotepa)、雷莫 司 丁(ranimustine)、尼莫司汀(nimustine)、Cloretazine™ (拉莫司 ί丁(laromustine))、AMD-473 ' 六甲鳴胺(altretamine) 、AP-5280、阿普淨酿(apaziquone)、伯斯坦尼辛 (brostallicin)、苯達莫司汀(bendamustine)、卡莫司、;丁 (carmustine)、雌氮芥(estramustine)、福莫司汀 147960.doc -55- 201041882 (fotemustine)、格魯福莫司汀(glufosfamide)、KW-2170、 馬碟酿胺(mafosfamide)、二漠衛矛醇(mitolactol)、洛莫司 iT (lomustine) ' 曲奥舒凡(treosulfan)、達卡巴0秦 (dacarbazine)及替莫0坐胺(temozolomide)。 抗代謝物之實例僅包含但不限於曱胺蝶吟(methotrexate) 、6-毓基嘌呤核苷、酼基嘌呤、5-氟尿嘧啶(5-FU)或與甲 醯四氫葉酸、替加氟(tegafur)、UFT、去氧氟尿苷 (doxifluridine)、卡莫氟(carmofur)、阿糖胞苷(cytarabine)、 阿糖胞苦十八烧基磷酸納(cytarabine ocfosfate)、依諾他濱 (enocitabine)、S-1、培美曲 °坐(pemetrexed)、吉西他濱 (gemcitabine)、氟達拉濱(fludarabine)、5-阿札胞苦(5-azacitidine)、卡培他濱(capecitabine)、克拉屈濱(cladribine) 、氯苯吩唤(clofarabine)、地西他濱(decitabine)、依氟鳥 胺酸(eflornithine)、乙稀基胞苦、阿拉伯糖胞皆、經基 腺、TS-1、美法命(melphalan)、财拉濱(nelarabine)、諾拉 曲塞(nolatrexed)、培美曲塞二納(disodium pemetrexed)、 喷托他丁(pentostatin)、培裏克松(pelitrexol)、雷替曲塞 (raltitrexed)、非洛地平(triapine)、曲美沙特(trimetrexate) 、阿糖腺普(vidarabine)、黴盼酸、阿糖胞苦、喷托他丁 (pentostatin)、π塞唾吱林(tiazofurin)、病毒嗤(ribavirin)、 EICAR、經基脲及去鐵胺(deferoxamine) 〇 抗生素之實例包含但不限於插入式抗生素、阿柔比星 (aclarubicin)、放線菌素 D(actinomycin D)、氨柔比星 (amrubicin)、脂質體蒽環黴素(annamycin)、多柔比星 147960.doc -56- 201041882
〇 (adriamycin)、博來黴素(bleomycin)、柔紅黴素(daunorubicin) 、多柔比星(doxorubicin)(包含微脂體多柔比星)、依沙蘆 星(elsamitrucin)、表柔比星(epirubicin)、加柔比星 (galarubicin)、伊達比星(idarubicin)、絲裂黴素 C(mitomycin C)、奈莫柔比星(nemorubicin)、新制癌菌素 (neocarzinostatin)、培洛黴素(peplomycin)、°比柔比星 (pirarubicin)、雷貝卡黴素(rebeccamycin)、淨司他丁斯酯 (stimalamer)、鏈脲佐菌素(streptozocin)、伐蘆比星 (valrubicin)、淨司他丁(zinostatin)及其等組合。 拓撲異構酶抑制劑之實例包含但不限於阿柔比星 (aclarubicin)、氨萘非特(amonafide)、貝洛替康(belotecan) 、喜樹驗(camptothecin)、10-經基喜樹驗、9-胺基喜樹 驗、安π丫咬(amsacrine)、右雷佐生(dexrazoxane)、雙氟莫 替康(diflomotecan)、鹽酸伊立替康(irinotecan HC1)、印都 特卡瑞(edotecarin)、表柔比星(epirubicin)、依託泊苦 (etoposide)、依克沙替康(exatecan)、貝卡特卡瑞 (becatecarin)、吉馬替康(gimatecan)、勒托替康 (lurtotecan)、奥拉塞星(orathecin)、BN-80915、米托蒽酿 (mitoxantrone)、n比柔比星(pirarubicin)、匹善重(pixantrone) 、魯比替康(rubitecan)、索布佐生(sobuzoxane)、SN-38、 他氟普沙(tafluposide)及拓撲替康(topotecan)。 抗體之實例包含但不限於利妥昔單抗(rituximab)、西妥 昔單抗(cetuximab)、貝伐單抗(bevacizumab)、曲妥珠單抗 (trastuzumab)、CD40-特異性抗體及IGF1R-特異性抗體、 147960.doc -57- 201041882 chTNT-l/B、德奴單抗(denosumab)、依决洛單抗 (edrecolomab)、WX G250、扎木單抗(zanolimumab)、林妥 珠單抗(lintuzumab)及替茨立木單抗(ticilimumab)。 荷爾蒙療法之實例包含但不限於碳酸司維拉姆 (sevelamer carbonate)、瑞樂司坦(rilostane)、促黃激素釋 放激素、莫卓司坦(modrastane)、依西美坦(exemestane)、 乙酸亮丙瑞林(leuprolide acetate)、布舍瑞林(buserelin)、 西曲瑞克(cetrorelix)、地洛瑞林(deslorelin)、組胺瑞林 (histrelin)、阿那曲 °坐(anastrozole)、福斯瑞林(fosrelin)、 戈舍瑞林(goserelin)、地加瑞克(degarelix)、度骨化醇 (doxercalciferol)、法屈0坐(fadrozole)、福美司坦(formestane) 、他莫昔芬(tamoxifen)、阿佐昔芬(arzoxifene)、比卡魯胺 (bicalutamide)、阿巴瑞克(abarelix)、曲普瑞林(triptorelin) 、非那雄胺(finasteride)、氣維司群(fulvestrant)、托瑞米 芬(toremifene)、雷洛昔芬(raloxifene)、曲洛司坦(trilostane) 、拉索昔芬(lasofoxifene)、來曲0坐(letrozole)、It 利坦 (flutamide)、甲地孕嗣(megesterol)、米非司酮(mifepristone) 、尼魯米特(nilutamide)、地塞米松(dexamethasone)、強的 松(prednisone)及其它糖皮質激素。 類視黃醇或deltoids之實例包含但不限於西奥骨化醇 (seocalcitol)、來沙骨化醇(lexacalcitol)、芬維 A 胺 (fenretinide)、阿曲諾英(alitretinoin)、維生素 A 酸 (tretinoin)、貝沙羅汀(bexarotene)及 LGD-1 550。 植物驗之實例包含但不限於長春新驗(vincristine)、長春 147960.doc -58- 201041882 驗(vinblastine)、長春地辛(vindesine)及長春瑞濱 (vinorelbine) 〇 蛋白酶體抑制劑之實例包含但不限於波替單抗 (bortezomib)、MG-132、NPI-0052及 PR-171。 免疫製劑之實例包含但不限於干擾素及其他免疫增強 劑。干擾素包含干擾素α、干擾素a-2a、干擾素a-2b、干擾 素β、干擾素γ-la、干擾素γ-lb、干擾素γ-ηΐ及其等組合。 其他製劑包含惠爾血(filgrastim)、蘑菇多糖(lentinan)、西 索非蘭(sizofllan)、BCG live、烏苯美司(ubenimex)、WF-10(tetrachlorodecaoxide或 TCDO)、阿地白介素(aldesleukin) 、阿來組單抗(alemtuzumab)、BAM-002、達卡巴嗪 (dacarbazine)、達利珠單抗(daclizumab)、德尼白介素 (denileukin)、吉妥單抗(gemtuzumab ozogamicin)、替坦異 貝莫單抗(ibritumomab)、味喧莫特(imiquimod)、來格司亭 (lenograstim)、黑色素瘤疫苗(melanoma vaccine)、莫拉司 亭(molgramostim)、沙格司亭(sargramostim)、他索那明 (tasonermin)、替克白介素(tecleukin)、胸腺法新(thymalasin) 、托西莫單抗(tositumomab)、Lorus 醫藥之 VirulizinTM 免疫 療法、Z-100(Maruyama之特異性物質或 SSM)、Zevalin™ (替伊莫單抗(ibritumomab tiuxetan))、依e瓜佐單抗 (epratuzumab)、米托莫單抗(mitumomab)、歐雷哥浮馬 (oregovomab)、皮托莫單抗(pemtumomab)、Provenge™ (sipuleucel-T)、替西白介素(teceleukin)、Therocys™(卡介 苗(Bacillus Calmette-Guerin))、細胞毒性淋巴細胞抗原 147960.doc -59- 201041882 4(CTLA4)抗體及可阻斷CTLA4之製劑,例*Μ〇Χ_〇1〇。 生物反應調節劑之實例為調節活有機體之防禦機制或生 物反應,諸如組織細胞之存活、生長或分化以其等具有抗 腫瘤活性。此等製劑包含但不限於雲芝素(krestin)、蘑菇 多糖(lentinan)、西佐糖(siZ0firan)、溶鏈菌素(picibanil)、 PF-3512676及烏苯美司(ubenimex)。 癌咬類似物之實例包含但不限於5_氟尿嘧啶、氟尿芽、 去氧氟尿苷、雷替曲塞(raltitrexed)、阿糖胞苷(Cytarabine) 、阿拉伯糖胞苷(cytosine arabinoside)、氟達拉濱 (fludarabine)、三乙醯基尿苷、曲沙他濱(tr〇xacitabine)及 吉西他濱(gemcitabine)。 嗓呤類似物之實例包含但不限於巯基嘌呤及硫代烏嘌 〇 抗有絲分裂劑之實例包含但不限於Ν-(2-((4-羥苯基)胺 基)。比°定-3-基)-4-甲氧基笨項醯胺、紫杉醇(pacijtaxei)、多 西他赛(docetaxel)、拉洛他賽(iarotaxe丨)、埃坡黴素 D(epothilone D)、PNU-100940、巴他布林(batabulin)、伊 沙匹隆(ixabepilone)、帕 土匹隆(patUpil〇ne)、XRP-9881、 長春氟寧(vinflunine)及ZK-EPO(合成埃坡黴素)。 放射療法之實例包含但不限於體外射線束放射療法 (XBRT)、遠程療法、短程療法、密封源放射療法及非密 封源放射療法。
BiTE抗體為藉由同時結合兩細胞而使τ_細胞攻擊癌細胞 之雙特異性抗體。Τ-細胞隨後攻擊目標癌細胞。BiTE抗體 147960.doc •60· 201041882 之實例包含但不限於阿德木單抗(adecatumumab)(Micromet MT201)、不來木單抗(blinatumomab)(Micromet MT103) 等。未受理論限制’ T-細胞引起目標癌細胞之凋亡的其中 一機理為藉由包含穿洞素及顆粒酶B之溶細胞顆粒組分之 胞外分泌。於此,顯示Bcl-2衰減穿洞素及顆粒酶B引起的 凋亡。此等數據表明Bcl-2之抑制可增強τ-細胞靶向癌細胞 時所引起的細胞毒性作用(Sutton等人(1997) J. Immunol. 158:5783-5790) 〇 〇
SiRNA為具有内源RNA驗或化學上經改質的核苦酸之分 子。改質未消除細胞活性,而增強安定性及/或增加細胞 效力。化學改質之實例包含硫代磷酸酯基、2,_脫氧核苷 酸、含2’-〇CH3-之核糖核苷酸、2'-F-核糖核苷酸、2,-甲氧 基乙基核糖核苷酸、其組合等,siRNA可具有不同長度(例 如’ 10-200 bps)及結構(例如’發夾結構、單/雙股、凸 起、刻痕/間隙、失配)且於細胞中處理以提供活性基因沉 Q 默。雙股siRNA(dsRNA)之每一股(鈍端)或不對稱端(突出 物)具有相同數量的核苷酸。丨_2個核苷酸之突出物可存在 於有義氣及/或反義股上,及存在於給定股之5,_及/或3,_ 端。例如’顯示靶向Mel-Ι之siRNA可提高ABT-263之活性 (Tse 等人(2〇08) cancer Res· 68:3421-3428及文中參照)。 夕價結合蛋白為含有兩個或更多抗原結合點之結合蛋 白。多價結合蛋白經改造具有三個或更多個抗原結合點且 般不為自然發生的抗體。術語「多特異性結合蛋白」意 心可結合兩個或多個相關或不相關標靶之結合蛋白。雙可 I47960.doc -61 · 201041882 變域(DVD)結合蛋白為結合含有兩個或多個抗原結合點之 蛋白的四價或多價結合蛋白。此等DVD可為單特異性 (即,可結合一抗原)或多特異性(即,可結合兩或多個抗 原)。將含有兩重鏈DVD多肽及兩輕鏈DVD多肽之DVD結 合蛋白稱爲DVD Ig's。DVD Ig之每一半含有一重鏈DVD多 肽、一輕鏈DVD多肽、及兩個抗原結合點。每一結合點含 有一重鍵可變域及一輕鍵可變域且每一抗原結合處之抗原 結合總共涉及6個CDR。 PARP抑制劑包含但不限於ABT-888、奥拉派力伯 (olaparib)、KU-59436、AZD-2281、AG-014699、BSI-201、BGP-15、INO-lOOl、ONO-2231 等。 另或替代之,本發明之組合物可與選自以下之一或多種 抗癌劑以組合療法投與:ABT-1 00、N-乙醯基秋水仙醇-0-填酸S旨、阿曲丁(acitretin)、AE-941、糖苦配基原人參二 醇、阿格拉賓(arglabin)、三氧化二砷、AS04佐劑-經吸收 之HPV疫苗、L-天冬酿胺酸酶、阿納托。坐(atamestane)、阿 曲生坦(atrasentan)、AVE-8062、波生坦(bosentan)、堪佛 司非米德(canfosfamide)、CanvaxinTM、卡妥索單抗 (catumaxomab)、CeaVac™、西莫白介素(celmoleukin)、考 白他汀(combrestatin A4P)、肯特素拉德謹威(contusugene ladenovec)、Cotara™、環丙孕酮(cyproterone)、脫氧助間 型黴素(deoxycoformycin)、右雷佐生(dexrazoxane)、Ν,Ν-二乙基-2-(4-(苯曱基)苯氧基)乙胺、5,6-二甲基咕吨酮-4-乙酸、二十二礙六稀酸/紫杉醇、綿内醋(discodermolide)、 147960.doc •62- 201041882 乙丙昔羅(efaproxiral)、蒽雜他瑞(enzastaurin)、埃坡黴素 B(epothilone B)、乙炔基尿嘴咬、依昔舒林(exisulind)、發 利麥(falimarev)、Gastrimmune™、GMK 疫苗、GVAXTM、 鹵夫酮(halofuginone)、組胺(histamine)、經基脲 (hydroxycarbamide)、伊班膦酸(ibandronic acid)、替伊莫 單抗(ibritumomab tiuxetan)、IL-13-PE38、伊納利馬 (inalimarev)、介白素 4、KSB-3 11、蘭瑞肽(lanreotide)、 來那度胺(lenalidomide)、洛伐尼(lonafarnib)、洛伐他汀 (lovastatin)、5,10-亞曱基四氫葉酸、米伐木肽(mifamurtide) 、米替福新(miltefosine)、莫特沙芬(motexafin)、奥利默 森(oblimersen)、OncoVAXTM、Osidem™、經紫杉酵白蛋 白安定之奈米顆粒、聚楚胺酸紫杉醇(paclitaxel poliglumex)、帕米膦酸(pamidronate)、盤尼圖單抗 (panitumumab)、聚乙二醇化干擾素 a(peginterferon alfa)、 培加帕酶(pegaspargase)、脫氫雌馬酴(phenoxodiol)、聚 (I)-聚(C12U)、丙卡巴井(procarbazine)、豹虫圭酶(ranpirnase) 、内比馬斯塔(rebimastat)、重組四價HPV疫苗、角鯊胺 (squalamine)、星形孢菌素(staurosporine)、STn-KLH 疫 苗、T4核酸内切酶V、他扎羅汀(tazarotene)、6,6',7,12-四 曱氧基-2,2'-二曱基-1 β-berbaman、沙立度胺(thalidomide)、 TNFeradeTM、131I-托西莫單抗(131I-tositumomab)、曲貝特 汀(trabectedin)、三嗓酮(triazone)、腫瘤壞死因子、 UkrainTM、牛痘-MUC-1疫苗、L-纈胺酸-L-硼脯胺酸、 Vitaxin™、維特斯朋(vitespen)、°坐來膦酸(zoledronic 147960.doc -63- 201041882 acid)及佐柔比星(zorubicin)。 於一實施例中,將治療有效量之含有術_263雙棚之 本發明的組合物投與至有需要之個體以治療期間抗〉周亡 Bcl-2蛋白、抗调亡Bc1_Xl蛋白及抗阔亡Bd w蛋白中一或 多者係過度表達的疾病。 於另一實施例中,將治療有效量之含有八8丁_263雙—hci 之本發明的組合物投與至有需要之個體以治療異常細胞生 長及/或失調性〉周亡之疾病。 此等疾病之實例包含但不限於癌症、間皮瘤、膀耽癌、 胰腺癌、皮膚癌、腦或頸部腫瘤、表皮或眼内黑色素瘤、 卵巢癌乳癌、子呂癌、輸卵管癌瘤、子宮内膜癌瘤、子 宮頸癌、陰道癌、外陰癌、骨癌、結腸癌、直腸癌、肛門 區域癌、胃癌、胃腸(胃、結腸直腸及/或十二指腸)癌、慢 性淋巴細胞性白血病、急性淋巴細胞性白血病、食管癌、 小腸癌、内分泌系統癌 '甲狀腺癌、甲狀旁腺癌、腎上腺 癌、軟組織肉瘤、尿道癌、陰莖癌、睪丸癌、肝細胞(肝 臟及/或膽管)癌、原發性或次發性中樞神經系統腫瘤、原 發性或次發性腦腫瘤、霍奇金氏(Hodgkin's)病、慢性或急 性白血病、慢性粒細胞性白血病、淋巴球性淋巴瘤、淋巴 細胞白血病、濾泡淋巴瘤、T-細胞或B-細胞源之淋巴瘤、 黑色素瘤、多發性骨髓瘤、口腔癌、非小細胞肺癌、前列 腺癌、小細胞肺癌、腎及/或輸尿管癌、腎細胞癌、腎盂 癌、中樞神經系統腫瘤、原發性中樞神經系統淋巴瘤、非 霍奇金氏(Hodgkin's)淋巴瘤、脊柱瘤、腦幹膠質瘤、垂體 147960.doc -64- 201041882 腺瘤、腎上腺皮質癌、膽囊癌、脾癌、膽管癌、纖維肉 瘤、神經母細胞瘤、視網媒母細胞瘤或其等組合。 於一特定實施例中,將治療有效量之包含ABT-263雙-HC1的本發明組合物投與至需要其患者以治療膀胱癌、腦 癌、乳癌、骨藤癌、子宮頸癌、慢性淋巴細胞性白血病、 急性淋巴細胞性白血病、腸癌、食管癌、肝細胞癌、淋巴 細胞性白血病、濾泡淋巴瘤、T-細胞或B-細胞源之淋巴 瘤、黑色素瘤、粒細胞性白血病、骨髓瘤、口腔癌、卵巢 癌、非小細胞肺癌、前列腺癌、小細胞肺癌或脾癌。 根據此等任意實施例,將組合物與一種或多種其它治療 劑以單療法或組合療法投與。 例如,一種治療個體間皮瘤、膀胱癌、胰腺癌、皮膚 癌、腦或頸部腫瘤、表皮或眼内黑色素瘤、卵巢癌、乳 癌、子宮癌、輸卵管癌瘤、子宮内膜癌瘤、子宮頸癌、陰 道癌、外陰癌、骨癌、結腸癌、直腸癌、肛門區域癌、胃 癌、胃腸(胃、結腸直腸及/或十二指腸)癌、慢性淋巴細胞 性白血病、急性淋巴細胞性白血病、食管癌、小腸癌、内 分泌系統癌、甲狀腺癌、甲狀旁腺癌、腎上腺癌、軟組織 肉瘤、尿道癌、陰莖癌、睪丸癌、肝細胞(肝臟及/或膽管) 癌、原發性或次發性中樞神經系統腫瘤、原發性或次發性 腦腫瘤、霍奇金氏(Hodgkin’s)病、慢性或急性白血病、慢 )生粒細胞性白血病、淋巴球性淋巴瘤、淋巴細胞白血病、 濾泡淋巴瘤、τ_細胞或B —細胞源之淋巴瘤、黑色素瘤、多 發性骨髓瘤、口腔癌、非小細胞肺癌、前列腺癌、小細胞 147960.doc -65- 201041882 肺癌、腎及/或輸尿管癌、腎細胞癌、腎盂癌、中樞神經 系統腫瘤、原發性中樞神經系統淋巴瘤、非霍奇金氏 (Hodgkin's)淋巴瘤、脊柱瘤、腦幹膠質瘤、垂體腺瘤、腎 上腺皮質癌、膽囊癌、脾癌、膽管癌 '纖維肉瘤、神經母 細胞瘤、視網膜母細胞瘤或其等組合之方法,其包含對該 個體投與治療有效量之包含ABT-263雙-HC1及(b)依託泊苷 (etoposide)、長春新驗(vincristine)、CHOP、利妥昔單抗 (rituximab)、雷帕黴素(rapamycin)、R-CHOP、RCVP、 DA-EPOCH-R或波替單抗(bortezomib)中一者或多者之本發 明組合物。 於特定實施例中,將治療有效量之包含ABT-263雙-HC1 之本發明組合物與依託泊皆(etoposide)、長春新驗 (vincristine)、CHOP、利妥昔單抗(rituximab)、雷帕黴素 (rapamycin)、R-CHOP、RCVP、DA-EPOCH-R或波替單抗 (bortezomib)以單療法或組合療法投與至有需要之個體以 治療淋巴惡性腫瘤’諸如B-細胞淋巴瘤或非霍奇金氏 (Hodgkin's)淋巴瘤。 於其他特定實施例中,將治療有效量之包含ABT-263雙-HC1之本發明組合物與依託泊苷(etoposide)、長春新鹼 (vincristine)、CHOP、利妥昔單抗(rituximab)、雷帕黴素 (rapamycin)、R-CHOP、RCVP、DA-EPOCH-R或波替單抗 (bortezomib)以單療法或組合療法投與至有需要之個體以 治療慢性淋巴細胞性白血病或急性淋巴細胞性白血病。 本發明亦提供一種保持癌症患者血流中ABT-263及/或一 147960.doc •66- 201041882 種或多種其代謝物之治療有效血漿濃度之方法,其包含對 該個體投與如文中所述之醫藥組合物,其劑量量相杂於約 50至約500 mg ABT_263/天,平均投藥間隔為約3小時至約 7天。 ' 治療有效血漿濃度尤其取決於患者之特定癌症、此癌症 之階段、嚴重性及攻擊性、及需要的結果(例如,稃定、 腫瘤生長減慢、腫瘤縮小、轉移的風險性降低等)。最佳 為當血漿濃度足以就治療癌症而言提供益處時,不應足以 ® 引起不利的副作用至不受歡迎或無法忍受的程度。 為治療常見癌症及淋巴惡性腫瘤,諸如特定言之非霍奇 金氏(Hodgkin’s)淋巴瘤,在大多數情況中,ABT-263之血 漿浪度應保持在約0.5至約1〇 pg/mi。因此,在abt-263療 法期間’穩態Cmax —般不應超過約1〇 pg/mi,且穩態cmin一 般不應低於約0.5 pg/ml。進一步發現最佳挑取以上提供範 圍内之日劑量量及以有效提供穩態下不大於約5,例如不 Q 大於約3之Cmax/Cmin比的平均投藥間隔。應了解更長的投 藥間隔將得到更大的cmax/cmin比。具體而言,穩態下,本 發明指約3至約8 gg/ml之ABT-263 Cmax及約1至約5 pg/ml - 之 Cmin。 根據本發明,有效保持治療有效ABT-263血漿濃度之曰 劑量量為約50至約500 mg。於大多數情況中,適宜的曰劑 量量為約200至約400 mg。具體而言,日劑量量可例如為 約 50、約 1〇〇、約150、約 200、約 250、約 300、約 350、約 400 ' 約 450或約 500 mg ° 147960.doc -67- 201041882 有效保持治療有效ABT-263血漿濃度之平均投藥間隔為 約3小時至約7天。於大多數情況中,適宜的平均投藥間隔 為約8小時至約3天,或約12小時至約2天。通常適宜的為 每曰一次(q.d.)的投與。 於其他實施例中,根據本發明之投與可餵有或未餵有食 物,即非禁食或禁食狀態。一般最佳將本發明組合物投與 至非禁食患者。 關於本發明之進一步信息可獲自Tse等人(2008) Cancer Res. 68:3421-3428近期發表的文章且其補充資料在線獲自 Cancer Research(cancerres.aacrjournals.org/)。該文章及其 補充資料之全文係以引入的方式併入文中。 【圖式簡單說明】 圖1為ABT-263雙-HC1晶型I之PXRD掃描圖;及 圖2為ABT-263雙-HC1晶型II之PXRD掃描圖。 147960.doc 68-
Claims (1)
- 201041882 七、申請專利範圍: 1· 一種化合物N-(4-(4-((2-(4-氯苯基)-5,5-二甲基-1-環己-i_ 婦-1·基)甲基)哌嗪-1-基)苯甲醯基 基)_〗-((苯基硫)甲基)丙基)胺基-3-((三氟甲基)磺醯基)苯 績酿胺雙鹽酸鹽(ABT-263雙-HC1)。 2·如請求項1之化合物,其係呈固態形式。 3·如請求項1之化合物,其以每毫升介質至少約}毫克ΑΒτ_ 263游離鹼等效物之濃度於助溶介質中呈增溶形式。4. 如請求項1之化合物,呈其結晶多晶型〗,其特徵至少為 粉末X-射線繞射峰於以下位置之任一處或多處:6 8、 7.2、8.5、18.5及 18.7 〇2θ,±〇·2 °2Θ。 5. 如請求項4之結晶多晶型,立胜料 夕日日i其特徵至少為粉末X-射線繞 射峰係於上述每一位置。 ❹ 6·之結晶多晶型’其特徵在於粉末X-射線繞射 圖實質上係如以下表所示147960.doc 201041882 7·如凊求項1之化合物,呈其結晶多晶型π,其特徵至少為 叙末乂_射線繞射峰係於3.7或7.4。20,±〇.2。20。 8. 如凊求項7之多晶型,其特徵至少為粉末X-射線繞射峰 係於3.7與7.4。20,±()2。20。 9. 如凊求項7之多晶型,其特徵為粉末χ_射線繞射圖實質 上係如下表所示: _ 峰位置(02θ) 相對強度 -__3.7 6.0 __7.4 100.0 __12.1 5.3 __15.6 8.6 16.1 16.2 16.6 21.6 __18.3 70.2 - 19.0 13.4 1〇.種如β青求項1之化合物,其係溶劑化物晶體,其包含 經有機溶劑溶劑化之ΑΒΤ—263雙-HC1。 11. 如《月求項1G之溶劑化物,其中該有機溶劑係、選自由乙 醇、“丙醇、2-丙醇、2_丁醇、第三丁醇、硝基甲烷、 乙腈、丙腈、甲酸乙醋、乙酸甲醋、乙酸乙酯、乙酸1 :醋、丙嗣、甲基乙基酮、甲基異丙酮m 笨、甲苯’及丁基鍵組成之群。 12· 一種製備如請求項4之結晶多晶型之方法,其包含脫去 ABT-263雙-HC1之乙醇、卜丙醇、2,醇、2 丁醇、第三 丁醇、乙腈、丙腈'甲酸乙醋、乙酸甲酿、乙酸乙醋、 酸異丙醋、丙酮、甲基異丙,、1,4-二。惡烧、笨、甲 本或丁基謎溶劑化物之溶劑。 I47960.doc 201041882 13. 14. 15. 16. 〇 17. 18. 19. Ο 20. 21. 一種製備如請求項7之結晶多晶型的方法,其包含ΑΒΤ-雙HC1之甲基乙基酮溶劑化物的脫溶劑化。 一種醫藥組合物’其包含ABT-263雙_HC1及一種或多種 醫藥上可接受的賦形劑。 如晴求項14之組合物’其包含abT-263雙-HC1之結晶多 晶型I。 如吻求項14之組合物,其包含ABT-263雙-HC1之結晶多 晶型II。 如請求項14之組合物’其包含ABT-263雙-HC1於包含脂 溶劑之載劑中的溶液。 一種ABT-263雙-HC1或包含ΛΒΤ-263雙-HC1及一種或多 種醫藥上可接受的賦形劑之醫藥組合物的用途,其係用 於治療以抗〉周亡Bcl-2家族蛋白之阔亡功能紊亂及/或過 度表達爲特徵的疾病,此係藉由對患有該疾病的個體投 與治療有效量之ABT-263雙-HC1或該醫藥組合物。 如請求項18之用途,其中該或該醫藥組 合物係經口、非經腸、舌下、經頰、鼻内、經肺、局 部、經皮、皮内、經眼、經耳、經直腸、經陰道、胃 内、顱内、滑囊腔内或關節内途徑投與。 如請求項18或請求項19之用途,其中該痂戚氣 T邊疾病為贅瘤性疾 病。 如請求項20之用途’其中該贅瘤性疾病係選 •曰田癌症、 間皮瘤、膀胱癌、胰腺癌、皮膚癌、腦或頸部腫瘤 皮或眼内黑色素瘤、卵巢癌、乳癌、子宮声、 』、輸卵管癌 147960.doc 201041882 瘤、子宮内膜癌瘤、子宮頸癌、陰道癌、外陰癌、骨 癌、結腸癌、直腸癌、肛門區域癌、胃癌、胃腸(胃、結 腸直腸及/或十二指腸)癌、慢性淋巴細胞性白血病、急 性淋巴細胞性白血病、食管癌、小腸癌、内分泌系統 癌、曱狀腺癌、甲狀旁腺癌、腎上腺癌'軟組織肉瘤、 尿道癌、陰莖癌、睪丸癌、肝細胞(肝臟及/或膽管)癌、 原發性或次發性中樞神經系統腫瘤、原發性或次發性腦 腫瘤、霍奇金氏(Hodgkin's)病、慢性或急性白血病、慢 性粒細胞性白血病、淋巴球性淋巴瘤、淋巴細胞白血 病、濾泡淋巴瘤、T_細胞或B —細胞源之淋巴瘤、黑色素 瘤、多發性骨髓瘤、口腔癌、非小細胞肺癌、前列腺 癌、小細胞肺癌、腎及/或輸尿管癌、腎細胞癌、腎盂 癌、中樞神經系統腫瘤、原發性中樞神經系統淋巴瘤、 非霍奇金氏(Hodgkin’s)淋巴瘤、脊柱瘤' 腦幹膠質瘤' 垂體腺瘤、腎上腺皮質癌、膽囊癌、脾癌、膽管癌、纖 維肉瘤、神經母細胞瘤、視網膜母細胞瘤及其等組合組 成之群。 22.如請求項20之用途,其中該贅瘤性疾病為淋巴惡性腫 瘤。 23·如請求項22之用途,其中該淋巴惡性腫瘤為非霍奇金氏 (Hodgkin's)淋巴瘤。 24. 如請求項20之用途,其中該贅瘤性疾病為慢性淋巴細胞 性白血病或急性淋巴細胞性白血病。 25. 如請求項18至24中任一項之用途,其中該組合物係以約 I47960.doc 201041882 50至約500 mg ABT-263游離鹼等效物/天之劑量經口投與 且平均治療間隔為約3小時至約7天。 26.如請求項18至24中任一項之用途,其中該組合物係以約 200至約400 mg ΑΒΤ-263游離鹼等效物/天之劑量每日經 口投與一次。147960.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17427409P | 2009-04-30 | 2009-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201041882A true TW201041882A (en) | 2010-12-01 |
Family
ID=42288743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW099113921A TW201041882A (en) | 2009-04-30 | 2010-04-30 | Salt of ABT-263 and solid-state forms thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US8362013B2 (zh) |
EP (1) | EP2424849A1 (zh) |
JP (1) | JP2012525433A (zh) |
KR (1) | KR20120005538A (zh) |
CN (1) | CN102414186A (zh) |
AR (1) | AR076509A1 (zh) |
AU (1) | AU2010242923A1 (zh) |
BR (1) | BRPI1014369A2 (zh) |
CA (1) | CA2758740A1 (zh) |
IL (1) | IL215472A0 (zh) |
MX (1) | MX2011011511A (zh) |
RU (1) | RU2011148521A (zh) |
SG (1) | SG175146A1 (zh) |
TW (1) | TW201041882A (zh) |
UY (1) | UY32598A (zh) |
WO (1) | WO2010127190A1 (zh) |
ZA (1) | ZA201107592B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | Abbott Gmbh & Co Kg | Bcl-2族群抑制劑之口服醫藥劑型 |
TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
CN102695702A (zh) | 2009-09-20 | 2012-09-26 | 雅培制药有限公司 | 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物 |
CA2780177A1 (en) * | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
CN102584744B (zh) * | 2011-01-06 | 2015-07-01 | 上海药明康德新药开发有限公司 | 4-(4-((2-(4-氯苯基)-5,5-二甲基环己基-1-烯)甲基)哌嗪-1-基)苯甲酸的合成方法 |
PT3027618T (pt) | 2013-07-30 | 2020-10-12 | Kronos Bio Inc | Polimorfo de inibidores de syk |
TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
SG10201805670QA (en) * | 2014-01-28 | 2018-08-30 | Buck Inst Res Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
WO2015157120A1 (en) * | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
NZ726365A (en) | 2014-07-14 | 2018-06-29 | Gilead Sciences Inc | Combinations for treating cancers |
TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
CN115028640A (zh) | 2017-08-25 | 2022-09-09 | 吉利德科学公司 | Syk抑制剂的多晶型物 |
KR20210131372A (ko) | 2019-02-22 | 2021-11-02 | 크로노스 바이오, 인코포레이티드 | Syk 억제제로서의 축합된 피라진의 고체 형태 |
CN115279375A (zh) | 2019-11-05 | 2022-11-01 | 艾伯维公司 | 用于以navitoclax治疗骨髓纤维化和mpn相关病症的给药方案 |
US20230157970A1 (en) * | 2021-11-19 | 2023-05-25 | Board Of Regents, The University Of Texas System | Targeted Therapy of Kidney Fibrosis |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US630663A (en) * | 1899-05-01 | 1899-08-08 | Wallace George Cook | Combined hay and stock rack. |
US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5759548A (en) * | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
MX2007014049A (es) * | 2005-05-12 | 2008-02-11 | Abbott Lab | Activadores de apoptosis. |
CN101346128B (zh) * | 2005-10-25 | 2013-10-02 | 雅培制药有限公司 | 包含低水溶解度药物的配方及其使用方法 |
WO2009073835A1 (en) | 2007-12-06 | 2009-06-11 | Abbott Laboratories | Oral compositions of abt-263 for treating cancer |
CN101220008B (zh) | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
US20100278921A1 (en) * | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
RU2012101627A (ru) * | 2009-06-18 | 2013-07-27 | Эбботт Лэборетриз | Стабильная суспензия лекарственного средства в виде наночастиц |
CN102695702A (zh) * | 2009-09-20 | 2012-09-26 | 雅培制药有限公司 | 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物 |
CN101798292A (zh) | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
-
2010
- 2010-04-29 US US12/770,345 patent/US8362013B2/en not_active Expired - Fee Related
- 2010-04-30 JP JP2012508757A patent/JP2012525433A/ja not_active Withdrawn
- 2010-04-30 BR BRPI1014369A patent/BRPI1014369A2/pt not_active IP Right Cessation
- 2010-04-30 TW TW099113921A patent/TW201041882A/zh unknown
- 2010-04-30 CA CA2758740A patent/CA2758740A1/en not_active Abandoned
- 2010-04-30 WO PCT/US2010/033072 patent/WO2010127190A1/en active Application Filing
- 2010-04-30 AU AU2010242923A patent/AU2010242923A1/en not_active Abandoned
- 2010-04-30 CN CN2010800185934A patent/CN102414186A/zh active Pending
- 2010-04-30 AR ARP100101467A patent/AR076509A1/es not_active Application Discontinuation
- 2010-04-30 RU RU2011148521/04A patent/RU2011148521A/ru unknown
- 2010-04-30 KR KR1020117028610A patent/KR20120005538A/ko not_active Application Discontinuation
- 2010-04-30 SG SG2011073632A patent/SG175146A1/en unknown
- 2010-04-30 UY UY0001032598A patent/UY32598A/es not_active Application Discontinuation
- 2010-04-30 EP EP10717392A patent/EP2424849A1/en not_active Withdrawn
- 2010-04-30 MX MX2011011511A patent/MX2011011511A/es not_active Application Discontinuation
-
2011
- 2011-10-02 IL IL215472A patent/IL215472A0/en unknown
- 2011-10-17 ZA ZA2011/07592A patent/ZA201107592B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2758740A1 (en) | 2010-11-04 |
UY32598A (es) | 2010-12-31 |
IL215472A0 (en) | 2011-12-29 |
BRPI1014369A2 (pt) | 2016-04-05 |
AR076509A1 (es) | 2011-06-15 |
ZA201107592B (en) | 2012-06-27 |
CN102414186A (zh) | 2012-04-11 |
KR20120005538A (ko) | 2012-01-16 |
US20100305125A1 (en) | 2010-12-02 |
EP2424849A1 (en) | 2012-03-07 |
SG175146A1 (en) | 2011-11-28 |
US8362013B2 (en) | 2013-01-29 |
WO2010127190A1 (en) | 2010-11-04 |
RU2011148521A (ru) | 2013-06-10 |
AU2010242923A1 (en) | 2011-11-17 |
MX2011011511A (es) | 2011-11-18 |
JP2012525433A (ja) | 2012-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI488853B (zh) | Abt-263之結晶形式 | |
TW201041882A (en) | Salt of ABT-263 and solid-state forms thereof | |
RU2530642C2 (ru) | Стабилизированная липидная препаративная форма промотора апоптоза | |
TW201041883A (en) | Solid oral formulation of ABT-263 | |
CN102655858B (zh) | Abt-263胶囊 |